struct_id,strength,trade_name,applicant,appl_type,appl_no,approval_date,type,dose_form,route,exclusivity_date,description
144,EQ 137MG BASE,GOCOVRI,ADAMAS OPERATIONS,N,208944,2017-08-24,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2024-08-24,TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSONS DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
4188,100MG/ML,FERRIPROX,CHIESI,N,208030,2015-09-09,RX,SOLUTION,ORAL,2028-04-30,TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
5461,120MG,LUMAKRAS,AMGEN INC,N,214665,2021-05-28,RX,TABLET,ORAL,2026-05-28,NEW CHEMICAL ENTITY
5372,"50MG,37.5MG,25MG; 75MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2021-06-08,RX,TABLET,ORAL,2024-06-08,NEW PATIENT POPULATION
4716,EQ 10MG BASE,ICLUSIG,TAKEDA PHARMS USA,N,203469,2020-12-18,RX,TABLET,ORAL,2023-12-18,CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS
5301,80MG,XOFLUZA,GENENTECH INC,N,210854,2021-03-18,RX,TABLET,ORAL,2023-10-24,NEW CHEMICAL ENTITY
4302,0.16MG/INH;0.0048MG/INH;0.009MG/INH,BREZTRI AEROSPHERE,ASTRAZENECA AB,N,212122,2020-07-23,RX,"AEROSOL, METERED",INHALATION,2023-07-23,NEW COMBINATION
5334,300MG,NUBEQA,BAYER HEALTHCARE,N,212099,2019-07-30,RX,TABLET,ORAL,2024-07-30,NEW CHEMICAL ENTITY
5400,EQ 20MG BASE/VIAL,BYFAVO,ACACIA,N,212295,2020-10-06,RX,POWDER,INTRAVENOUS,2025-10-06,NEW CHEMICAL ENTITY
5243,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2026-10-30,PEDIATRIC EXCLUSIVITY
1539,EQ 50MG BASE;300MG,DOVATO,VIIV HLTHCARE,N,211994,2019-04-08,RX,TABLET,ORAL,2023-08-06,TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
4810,140MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2026-02-24,PEDIATRIC EXCLUSIVITY
4228,150MG,KALYDECO,VERTEX PHARMS,N,203188,2012-01-31,RX,TABLET,ORAL,2027-12-21,"FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS AND OLDER WHO HAVE ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020"
5133,50MG,VENCLEXTA,ABBVIE,N,208573,2016-04-11,RX,TABLET,ORAL,2026-05-15,TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
3128,360MG,JADENU,NOVARTIS PHARMS CORP,N,206910,2015-03-30,RX,TABLET,ORAL,2023-07-23,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3
392,32MG,TRACLEER,ACTELION,N,209279,2017-09-05,RX,"TABLET, FOR SUSPENSION",ORAL,2024-09-05,"TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY"
5046,EQ 20MG BASE,COTELLIC,GENENTECH INC,N,206192,2015-11-10,RX,TABLET,ORAL,2026-01-28,PEDIATRIC EXCLUSIVITY
4801,EQ 50MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2030-03-16,TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
2140,EQ 11.25MG BASE;69MG,QSYMIA,VIVUS,N,022580,2012-07-17,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-06-24,NEW PATIENT POPULATION
768,EQ 25MG BASE,PROCYSBI,HORIZON,N,203389,2013-04-30,RX,"CAPSULE, DELAYED RELEASE",ORAL,2025-06-22,PEDIATRIC EXCLUSIVITY
5352,EQ 1GM BASE/VIAL,FETROJA,SHIONOGI INC,N,209445,2019-11-14,RX,POWDER,INTRAVENOUS,2024-11-14,NEW CHEMICAL ENTITY
5262,240MG/12ML (20MG/ML),PREVYMIS,MERCK SHARP DOHME,N,209940,2017-11-08,RX,SOLUTION,INTRAVENOUS,2030-06-05,FOR PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
4746,1MG,POMALYST,BRISTOL,N,204026,2013-02-08,RX,CAPSULE,ORAL,2027-05-14,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
4801,EQ 75MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2024-12-22,PEDIATRIC EXCLUSIVITY
768,EQ 75MG BASE,PROCYSBI,HORIZON,N,203389,2013-04-30,RX,"CAPSULE, DELAYED RELEASE",ORAL,2023-02-14,PEDIATRIC EXCLUSIVITY
4634,14MG,AUBAGIO,SANOFI AVENTIS US,N,202992,2012-09-12,RX,TABLET,ORAL,2024-04-30,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
5447,EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML),ZEGALOGUE (AUTOINJECTOR),ZEALAND PHARMA,N,214231,2021-03-22,RX,SOLUTION,SUBCUTANEOUS,2026-03-22,NEW CHEMICAL ENTITY
2446,100MG/VIAL,FYARRO,AADI,N,213312,2021-11-22,RX,POWDER,INTRAVENOUS,2024-11-22,NEW PRODUCT
4802,EQ 1MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,DISCN,TABLET,ORAL,2024-06-22,"TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER  WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST"
2706,EQ 7.5MG BASE;46MG,QSYMIA,VIVUS,N,022580,2012-07-17,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-06-24,NEW PATIENT POPULATION
1225,0.055MG/INH;EQ 0.014MG BASE/INH,AIRDUO DIGIHALER,TEVA PHARM,N,208799,2019-07-12,RX,POWDER,INHALATION,2025-01-09,PEDIATRIC EXCLUSIVITY
25,300MG,ONUREG,BRISTOL,N,214120,2020-09-01,RX,TABLET,ORAL,2023-09-01,NEW PRODUCT
5344,200MG,PRETOMANID,MYLAN IRELAND LTD,N,212862,2019-08-14,RX,TABLET,ORAL,2024-08-14,NEW CHEMICAL ENTITY
3483,100MG,NOXAFIL,MERCK SHARP DOHME,N,205053,2013-11-25,RX,"TABLET, DELAYED RELEASE",ORAL,2024-06-17,FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
5202,1MG,OLUMIANT,ELI LILLY AND CO,N,207924,2019-10-08,RX,TABLET,ORAL,2025-06-13,TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
4801,EQ 50MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2025-06-22,"DABRAFENIB IS INDICATED IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS"
3317,5MG,REVLIMID,CELGENE,N,021880,2005-12-27,RX,CAPSULE,ORAL,2026-05-28,INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
4801,EQ 50MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2025-10-30,PEDIATRIC EXCLUSIVITY
4802,EQ 2MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2030-03-16,TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
5014,2MG,REXULTI,OTSUKA,N,205422,2015-07-10,RX,TABLET,ORAL,2026-05-10,TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
5446,2MG,PONVORY,JANSSEN PHARMS,N,213498,2021-03-18,RX,TABLET,ORAL,2026-03-18,NEW CHEMICAL ENTITY
322,12.5MG,BENZNIDAZOLE,CHEMO RESEARCH SL,N,209570,2017-08-29,RX,TABLET,ORAL,2024-08-29,FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
4550,0.42-8.33mCi/ML,FLUORODOPA F18,FEINSTEIN,N,200655,2019-10-10,RX,SOLUTION,INTRAVENOUS,2024-10-10,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY
4811,150MG/PACKET,SOVALDI,GILEAD SCIENCES INC,N,212480,2019-08-28,RX,PELLETS,ORAL,2024-10-07,PEDIATRIC EXCLUSIVITY
5351,EQ 100MG BASE,REYVOW,ELI LILLY AND CO,N,211280,2020-01-31,RX,TABLET,ORAL,2025-01-31,NEW CHEMICAL ENTITY
5506,EQ 20MG BASE,PYRUKYND,AGIOS PHARMS INC,N,216196,2022-02-17,RX,TABLET,ORAL,2029-02-17,TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
4715,EQ 20MG BASE,CABOMETYX,EXELIXIS INC,N,208692,2016-04-25,RX,TABLET,ORAL,2028-09-17,THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
5244,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2023-02-03,PEDIATRIC EXCLUSIVITY
3317,25MG,REVLIMID,CELGENE,N,021880,2006-06-29,RX,CAPSULE,ORAL,2024-02-22,"TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)"
3317,5MG,REVLIMID,CELGENE,N,021880,2005-12-27,RX,CAPSULE,ORAL,2024-02-22,"TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)"
2820,EQ 100MG BASE,QELBREE,SUPERNUS PHARMS,N,211964,2021-04-02,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2026-04-02,NEW CHEMICAL ENTITY
432,200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML),ZYNRELEF KIT,HERON THERAPS INC,N,211988,2021-05-12,RX,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2024-05-12,NEW PRODUCT
4802,EQ 2MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2025-05-04,"TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS"
247,110MG/VIAL,ARTESUNATE,AMIVAS,N,213036,2020-05-26,RX,POWDER,INTRAVENOUS,2027-05-26,INDICATED FOR THE INITIAL TREATMENT OF SEVERE MALARIA IN ADULT AND PEDIATRIC PATIENTS TO ALWAYS BE FOLLOWED BY A COMPLETE TREATMENT COURSE OF AN APPROPRIATE ORAL ANTIMALARIAL REGIMEN
776,EQ 150MG BASE/PACKET,PRADAXA,BOEHRINGER INGELHEIM,N,214358,2021-06-21,RX,PELLETS,ORAL,2024-06-21,NEW PRODUCT
1845,10MG/5ML,MORPHINE SULFATE,HIKMA,N,022195,2008-03-17,RX,SOLUTION,ORAL,2024-06-02,NEW PATIENT POPULATION
2706,EQ 3.75MG BASE;23MG,QSYMIA,VIVUS,N,022580,2012-07-17,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-06-24,NEW PATIENT POPULATION
4188,100MG/ML,FERRIPROX,CHIESI,N,208030,2015-09-09,RX,SOLUTION,ORAL,2024-04-30,TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
4228,25MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2019-04-29,RX,GRANULE,ORAL,2026-04-29,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
4801,EQ 75MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2030-03-16,TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
5300,EQ 0.25MG BASE,TALZENNA,PFIZER,N,211651,2018-10-16,RX,CAPSULE,ORAL,2023-10-16,NEW CHEMICAL ENTITY
4678,EQ 1.2GM BASE/VIAL,KIMYRSA,MELINTA THERAP,N,214155,2021-03-12,RX,POWDER,INTRAVENOUS,2019-08-06,NEW CHEMICAL ENTITY
4746,3MG,POMALYST,BRISTOL,N,204026,2013-02-08,RX,CAPSULE,ORAL,2027-05-14,FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
2419,0.055MG/INH;EQ 0.014MG BASE/INH,AIRDUO DIGIHALER,TEVA PHARM,N,208799,2019-07-12,RX,POWDER,INHALATION,2025-01-09,PEDIATRIC EXCLUSIVITY
5408,250MG/5ML (50MG/ML),VILTEPSO,NIPPON SHINYAKU,N,212154,2020-08-12,RX,SOLUTION,INTRAVENOUS,2025-08-12,NEW CHEMICAL ENTITY
4801,EQ 50MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2025-05-04,"TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS"
5243,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2026-04-30,"TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)"
5516,10MG/0.5ML (10MG/0.5ML),MOUNJARO,ELI LILLY AND CO,N,215866,2022-05-13,RX,SOLUTION,SUBCUTANEOUS,2027-05-13,NEW CHEMICAL ENTITY
4182,1MG/ML,XARELTO,JANSSEN PHARMS,N,215859,2021-12-20,RX,FOR SUSPENSION,ORAL,2024-12-20,NEW PRODUCT
5716,EQ 200MG BASE/VIAL,REZZAYO,CIDARA THERAPS,N,217417,2023-03-22,RX,POWDER,INTRAVENOUS,2035-03-22,GENERATING ANTIBIOTIC INCENTIVES NOW
4806,EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,TRINTELLIX,TAKEDA PHARMS USA,N,204447,2013-09-30,DISCN,TABLET,ORAL,2023-11-13,INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402
5330,20MG,XPOVIO,KARYOPHARM THERAPS,N,212306,2019-07-03,RX,TABLET,ORAL,2027-12-18,"FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, EXCLUDING ADULT PATIENTS COVERED BY XPOVIOS PREVIOUS INDICATION FOR MULTIPLE MYELOMA APPROVED ON JULY 3, 2019"
5243,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2023-02-03,PEDIATRIC EXCLUSIVITY
5709,100MG,JAYPIRCA,LOXO ONCOL,N,216059,2023-01-27,RX,TABLET,ORAL,2030-01-27,"TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR"
5733,100MG/15ML (6.7MG/ML),QALSODY,BIOGEN MA,N,215887,2023-04-25,RX,SOLUTION,INTRATHECAL,2028-04-25,NEW CHEMICAL ENTITY
5328,200MG,VIJOICE,NOVARTIS,N,215039,2022-04-05,RX,TABLET,ORAL,2024-05-24,NEW CHEMICAL ENTITY
5383,EQ 0.92MG BASE,ZEPOSIA,CELGENE INTL,N,209899,2020-03-25,RX,CAPSULE,ORAL,2024-05-27,FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS
4810,420MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2025-08-24,NEW PATIENT POPULATION
4175,2.5MG;1GM,JENTADUETO XR,BOEHRINGER INGELHEIM,N,208026,2016-05-27,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-03-30,ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5262,480MG/24ML (20MG/ML),PREVYMIS,MERCK SHARP DOHME,N,209940,2017-11-08,RX,SOLUTION,INTRAVENOUS,2030-06-05,FOR PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
3317,15MG,REVLIMID,CELGENE,N,021880,2006-06-29,RX,CAPSULE,ORAL,2024-02-22,"TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)"
5202,4MG,OLUMIANT,ELI LILLY AND CO,N,207924,2022-05-10,RX,TABLET,ORAL,2025-05-10,"TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)"
4187,250MG,XALKORI,PF PRISM CV,N,202570,2011-08-26,RX,CAPSULE,ORAL,2025-07-14,"TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH UNRESECTABLE, RECURRENT OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE"
5154,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
4228,150MG,KALYDECO,VERTEX PHARMS,N,203188,2012-01-31,RX,TABLET,ORAL,2024-07-31,"TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T"
5468,0.4MG,BYLVAY,ALBIREO,N,215498,2021-07-20,RX,CAPSULE,ORAL,2030-06-13,TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
768,EQ 300MG BASE/PACKET,PROCYSBI,HORIZON,N,213491,2020-02-14,RX,"GRANULE, DELAYED RELEASE",ORAL,2023-02-14,PEDIATRIC EXCLUSIVITY
776,EQ 110MG BASE,PRADAXA,BOEHRINGER INGELHEIM,N,022512,2015-11-20,RX,CAPSULE,ORAL,2024-06-21,TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR AT LEAST 5 DAYS AND TO REDUCE THE RISK OF RECURRENCE OF VTE IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN PREVIOUSLY TREATED
328,5%;1.2%,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,ENCUBE,A,212433,2021-04-28,RX,GEL,TOPICAL,2023-03-13,COMPETITIVE GENERIC THERAPY
4223,20MG,VIIBRYD,ABBVIE,N,022567,2011-01-21,RX,TABLET,ORAL,2023-07-31,PEDIATRIC EXCLUSIVITY
5128,1GM IRON/20ML (50MG IRON/ML),INJECTAFER,AM REGENT,N,203565,2021-04-28,RX,SOLUTION,INTRAVENOUS,2026-05-31,TREATMENT OF IRON DEFICIENCY IN ADULT PATIENTS WITH HEART FAILURE AND NEW YORK HEARTASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY
1123,2MG/0.85ML (2MG/0.85ML),BYDUREON BCISE,ASTRAZENECA AB,N,209210,2017-10-20,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2025-01-22,PEDIATRIC EXCLUSIVITY
5379,300MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2025-01-09,NEW CHEMICAL ENTITY
4175,2.5MG;850MG,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2026-06-20,"REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST"
4810,560MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,DISCN,TABLET,ORAL,2029-08-24,TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
1832,0.005MG/INH;0.05MG/INH,DULERA,ORGANON LLC,N,022518,2019-08-12,RX,"AEROSOL, METERED",INHALATION,2023-02-12,PEDIATRIC EXCLUSIVITY
5232,3.12MG/1.56ML (2MG/ML),TYMLOS,RADIUS HEALTH INC,N,208743,2017-04-28,RX,SOLUTION,SUBCUTANEOUS,2024-09-20,INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION
4873,200MG/VIAL,SIVEXTRO,CUBIST PHARMS LLC,N,205436,2014-06-20,RX,POWDER,INTRAVENOUS,2024-06-20,GENERATING ANTIBIOTIC INCENTIVES NOW
5305,EQ 25MG BASE,VITRAKVI,BAYER HLTHCARE,N,210861,2018-11-26,RX,CAPSULE,ORAL,2025-11-26,INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
4881,15MG,BELSOMRA,MERCK SHARP DOHME,N,204569,2014-08-13,RX,TABLET,ORAL,2023-01-29,"INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE"
5243,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
2552,EQ 1MG BASE/PACKET,PROGRAF,ASTELLAS,N,210115,2018-05-24,RX,FOR SUSPENSION,ORAL,2028-07-16,FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANT
5695,,XENOVIEW,POLAREAN,N,214375,2022-12-23,RX,GAS,INHALATION,2027-12-23,NEW CHEMICAL ENTITY
5253,1GM/VIAL;1GM/VIAL,VABOMERE,REMPEX,N,209776,2017-08-29,RX,POWDER,INTRAVENOUS,2022-08-29,NEW CHEMICAL ENTITY
1676,60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML),ZYNRELEF KIT,HERON THERAPS INC,N,211988,2021-05-12,DISCN,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2024-05-12,NEW PRODUCT
5379,25MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2021-06-16,RX,TABLET,ORAL,2024-06-16,TREATMENT OF ADULT PATIENTS WITH MAST CELL LEUKEMIA (MCL)
5010,188MG/PACKET;150MG/PACKET,ORKAMBI,VERTEX PHARMS INC,N,211358,2018-08-07,RX,GRANULE,ORAL,2025-09-02,NEW PATIENT POPULATION
2738,300MG,CUVRIOR,ORPHALAN,N,215760,2022-04-28,RX,TABLET,ORAL,2029-04-28,TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
5448,EQ 7.8MG BASE;EQ 39.2MG BASE,AZSTARYS,COMMAVE THERAP,N,212994,2021-05-07,RX,CAPSULE,ORAL,2026-05-07,NEW CHEMICAL ENTITY
4903,EQ 150MG BASE,OFEV,BOEHRINGER INGELHEIM,N,205832,2014-10-15,RX,CAPSULE,ORAL,2023-03-09,TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
4190,EQ 5MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2025-12-19,REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
5430,EQ 150MG BASE,ORLADEYO,BIOCRYST,N,214094,2020-12-03,RX,CAPSULE,ORAL,2025-12-03,NEW CHEMICAL ENTITY
4175,2.5MG;850MG,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2023-03-30,ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
841,18MG/9HR,XELSTRYM,NOVEN PHARMS INC,N,215401,2022-03-22,RX,SYSTEM,TRANSDERMAL,2025-03-22,NEW PRODUCT
4228,"100MG,75MG,50MG; 150MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2019-10-21,RX,TABLET,ORAL,2027-12-21,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
5353,80MG,BRUKINSA,BEIGENE,N,213217,2019-11-14,RX,CAPSULE,ORAL,2028-08-31,TREATMENT OF ADULT PATIENTS WITH WALDENSTRӦM’S MACROGLOBULINEMIA (WM)
5233,30MG,ALUNBRIG,TAKEDA PHARMS USA,N,208772,2017-04-28,RX,TABLET,ORAL,2027-05-22,"FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB"
5110,EQ 123MG BASE,GALAFOLD,AMICUS THERAP US,N,208623,2018-08-10,RX,CAPSULE,ORAL,2025-08-10,INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
4715,EQ 40MG BASE,CABOMETYX,EXELIXIS INC,N,208692,2016-04-25,RX,TABLET,ORAL,2028-09-17,THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
5462,EQ 150MG BASE,BREXAFEMME,SCYNEXIS,N,214900,2021-06-01,RX,TABLET,ORAL,2025-11-30,REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) INADULT AND POST-MENARCHAL PEDIATRIC FEMALES
5048,EQ 17.8MG BASE,WAKIX,HARMONY,N,211150,2019-08-14,RX,TABLET,ORAL,2024-08-14,NEW CHEMICAL ENTITY
5014,2MG,REXULTI,OTSUKA,N,205422,2015-07-10,RX,TABLET,ORAL,2024-12-27,NEW PATIENT POPULATION
5379,100MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2030-05-22,TREATMENT OF ADULT PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
4799,0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,TRELEGY ELLIPTA,GLAXOSMITHKLINE,N,209482,2020-09-09,RX,POWDER,INHALATION,2023-09-09,NEW STRENGTH
2706,EQ 11.25MG BASE;69MG,QSYMIA,VIVUS,N,022580,2012-07-17,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-06-24,NEW PATIENT POPULATION
5302,100MG,LORBRENA,PFIZER,N,210868,2018-11-02,RX,TABLET,ORAL,2025-11-02,INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
4802,EQ 0.5MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2025-10-30,PEDIATRIC EXCLUSIVITY
1725,500MG;EQ 50MG BASE,JANUMET XR,MERCK SHARP DOHME,N,202270,2012-02-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-06-04,PEDIATRIC EXCLUSIVITY
2448,1GM;EQ 50MG BASE,JANUMET,MSD SUB MERCK,N,022044,2007-03-30,RX,TABLET,ORAL,2024-06-04,PEDIATRIC EXCLUSIVITY
1725,5MG;1GM,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,2015-08-26,RX,TABLET,ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
5733,100MG/15ML (6.7MG/ML),QALSODY,BIOGEN MA,N,215887,2023-04-25,RX,SOLUTION,INTRATHECAL,2030-04-25,TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE
4922,EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL,ZERBAXA,CUBIST PHARMS LLC,N,206829,2014-12-19,RX,POWDER,INTRAVENOUS,2024-12-19,GENERATING ANTIBIOTIC INCENTIVES NOW
5287,EQ 500MG BASE/10ML (EQ 50MG BASE/ML),ZEMDRI,CIPLA USA,N,210303,2018-06-25,RX,SOLUTION,INTRAVENOUS,2028-06-25,GENERATING ANTIBIOTIC INCENTIVES NOW
4810,420MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2023-05-06,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
3302,65.2%,IODIXANOL,HENGRUI PHARMA,A,214271,2022-05-19,RX,INJECTABLE,INJECTION,2023-01-09,COMPETITIVE GENERIC THERAPY
5381,EQ 75MG BASE,NURTEC ODT,PFIZER,N,212728,2020-02-27,RX,"TABLET, ORALLY DISINTEGRATING",ORAL,2024-05-27,FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
2774,2.5%;1%,MYDCOMBI,EYENOVIA,N,215352,2023-05-05,RX,"SPRAY, METERED",OPHTHALMIC,2026-05-05,NEW PRODUCT
4810,70MG,IMBRUVICA,PHARMACYCLICS LLC,N,205552,2017-12-20,RX,CAPSULE,ORAL,2029-08-24,TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
4164,18MG/3ML (6MG/ML),SAXENDA,NOVO,N,206321,2014-12-23,RX,SOLUTION,SUBCUTANEOUS,2023-12-04,NEW PATIENT POPULATION
2552,EQ 5MG BASE/ML,PROGRAF,ASTELLAS,N,050709,1994-04-08,RX,INJECTABLE,INJECTION,2028-07-16,FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANT
4167,EQ 0.5MG BASE,FINGOLIMOD HYDROCHLORIDE,STRIDES PHARMA,A,207971,2020-06-29,DISCN,CAPSULE,ORAL,2023-03-20,PATENT CHALLENGE
1982,15MG;EQ 10MG BASE,LYBALVI,ALKERMES INC,N,213378,2021-05-28,RX,TABLET,ORAL,2026-05-28,NEW CHEMICAL ENTITY
1057,1MG;0.5MG;40MG,MYFEMBREE,MYOVANT SCIENCES,N,214846,2021-05-26,RX,TABLET,ORAL,2025-08-05,FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
5355,150MG,XCOPRI,SK LIFE,N,212839,2020-03-10,RX,TABLET,ORAL,2025-03-10,NEW CHEMICAL ENTITY
1725,1GM;EQ 50MG BASE,JANUMET XR,MERCK SHARP DOHME,N,202270,2012-02-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-06-04,PEDIATRIC EXCLUSIVITY
4805,EQ 50MG BASE;300MG,DOVATO,VIIV HLTHCARE,N,211994,2019-04-08,RX,TABLET,ORAL,2023-08-06,TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
2441,EQ 20MG BASE,REVATIO,VIATRIS,N,021845,2005-06-03,RX,TABLET,ORAL,2026-01-31,LABELING REGARDING NEW DOSING REGIMEN IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND TREATMENT OF PAH IN PEDIATRIC PATIENTS (AGES 1-17)
5460,15MG;EQ 10MG BASE,LYBALVI,ALKERMES INC,N,213378,2021-05-28,RX,TABLET,ORAL,2026-05-28,NEW CHEMICAL ENTITY
5313,EQ 10MG BASE/5ML (EQ 2MG BASE/ML),ONPATTRO,ALNYLAM PHARMS INC,N,210922,2018-08-10,RX,SOLUTION,INTRAVENOUS,2023-08-10,NEW CHEMICAL ENTITY
5267,2.4MG/0.75ML (2.4MG/0.75ML),WEGOVY,NOVO,N,215256,2021-06-04,RX,SOLUTION,SUBCUTANEOUS,2025-12-23,NEW PATIENT POPULATION
434,64MG/0.18ML (356MG/ML),BRIXADI,BRAEBURN,N,210136,2023-05-23,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2026-05-23,NEW PRODUCT
4811,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2023-03-19,NEW PATIENT POPULATION
4801,EQ 50MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2026-03-16,TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA WITH A BRAF V600 MUTATION WHO REQUIRE SYSTEMIC THERAPY
5010,125MG;200MG,ORKAMBI,VERTEX PHARMS INC,N,206038,2015-07-02,RX,TABLET,ORAL,2023-09-28,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
4811,200MG,SOVALDI,GILEAD SCIENCES INC,N,204671,2019-08-28,RX,TABLET,ORAL,2024-10-07,PEDIATRIC EXCLUSIVITY
4829,20MG,OTEZLA,AMGEN INC,N,205437,2014-03-21,RX,TABLET,ORAL,2024-12-20,"REVISIONS TO THE LABELING TO INCLUDE DATA FOR SUBJECTS WITH MILD TO MODERATE PLAQUE PSORIASIS, AND TO ALLOW FOR AN EXPANSION OF THE INDICATION"
5448,EQ 10.4MG BASE;EQ 52.3MG BASE,AZSTARYS,COMMAVE THERAP,N,212994,2021-05-07,RX,CAPSULE,ORAL,2026-05-07,NEW CHEMICAL ENTITY
4180,40MG/ML,DIFICID,CUBIST PHARMS LLC,N,213138,2020-01-24,RX,FOR SUSPENSION,ORAL,2023-01-24,NEW PRODUCT
597,2%;70%,SOLUPREP S,3M HEALTH CARE,N,208288,2018-08-08,OTC,SOLUTION,TOPICAL,2026-01-20,REVISIONS TO THE LABELING TO DESCRIBE MODIFIED FORMULATION BASED ON RESULTS OF STUDIES EM-05-014624 AND EM-05-014815
4830,10MG,JARDIANCE,BOEHRINGER INGELHEIM,N,204629,2014-08-01,RX,TABLET,ORAL,2025-08-24,PEDIATRIC EXCLUSIVITY
5361,50MG,UBRELVY,ABBVIE,N,211765,2019-12-23,RX,TABLET,ORAL,2024-12-23,NEW CHEMICAL ENTITY
5238,EQ 300MG BASE/VIAL,BAXDELA,MELINTA,N,208611,2017-06-19,RX,POWDER,INTRAVENOUS,2022-06-19,NEW CHEMICAL ENTITY
4899,45MG;200MG,HARVONI,GILEAD SCIENCES INC,N,205834,2019-08-28,RX,TABLET,ORAL,2024-10-07,PEDIATRIC EXCLUSIVITY
4382,50MG,MYRBETRIQ,APGDI,N,202611,2012-06-28,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-09-25,PEDIATRIC EXCLUSIVITY
4233,EQ 500MG BASE/5ML (EQ 100MG BASE/ML),BRIDION,MSD SUB MERCK,N,022225,2015-12-15,RX,SOLUTION,INTRAVENOUS,2024-01-22,REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P145
4228,125MG/PACKET;100MG/PACKET,ORKAMBI,VERTEX PHARMS INC,N,211358,2018-08-07,RX,GRANULE,ORAL,2025-09-02,NEW PATIENT POPULATION
1725,10MG;1GM,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,2016-12-09,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
2480,500MG/PACKET,DIACOMIT,BIOCODEX SA,N,207223,2018-08-20,RX,FOR SUSPENSION,ORAL,2025-07-14,NEW PATIENT POPULATION
4228,50MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2015-03-17,RX,GRANULE,ORAL,2024-07-31,"TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T"
841,13.5MG/9HR,XELSTRYM,NOVEN PHARMS INC,N,215401,2022-03-22,RX,SYSTEM,TRANSDERMAL,2025-03-22,NEW PRODUCT
4811,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2027-09-19,PEDIATRIC EXCLUSIVITY
5203,EQ 250MG BASE,RUBRACA,ZR PHARMA,N,209115,2017-05-01,RX,TABLET,ORAL,2023-05-15,TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
4175,5MG,TRADJENTA,BOEHRINGER INGELHEIM,N,201280,2011-05-02,RX,TABLET,ORAL,2023-03-30,ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
1802,100MG/100ML (1MG/ML),MIDAZOLAM IN 0.9% SODIUM CHLORIDE,HIKMA,A,216159,2023-04-17,RX,SOLUTION,INTRAVENOUS,2024-01-02,PATENT CHALLENGE
4907,100MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2023-05-08,"W/BEVACIZUMAB FOR MAINTENANCE TX OF ADULTS W/ADV. EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMO & CA ASSOCIATED W/ HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE STATUS"
5292,250MG,TIBSOVO,SERVIER,N,211192,2018-07-20,RX,TABLET,ORAL,2026-05-02,TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE >=75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
5461,120MG,LUMAKRAS,AMGEN INC,N,214665,2021-05-28,RX,TABLET,ORAL,2028-05-28,"TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY"
5521,1%,VTAMA,DERMAVANT SCI,N,215272,2022-05-23,RX,CREAM,TOPICAL,2027-05-23,NEW CHEMICAL ENTITY
1407,250MG;125MG,ADVIL DUAL ACTION WITH ACETAMINOPHEN,GLAXOSMITHKLINE,N,211733,2020-02-28,OTC,TABLET,ORAL,2023-02-28,NEW PRODUCT
5081,50MG;100MG,ZEPATIER,MSD SUB MERCK,N,208261,2016-01-28,RX,TABLET,ORAL,2024-12-09,NEW PATIENT POPULATION
4811,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2023-07-14,"INFORMATION ADDED TO THE LABELING DESCRIBING A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY/EFFICACY OF SOFOSBUVIR/VELPATASVIR IN SUBJECTS WITH CHRONIC HCV INFECTION WHO HAVE RECEIVED A LIVER TRANSPLANT"
4947,186MG,CRESEMBA,ASTELLAS,N,207500,2015-03-06,RX,CAPSULE,ORAL,2020-03-06,NEW CHEMICAL ENTITY
2806,24MG;26MG,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,2015-07-07,RX,TABLET,ORAL,2024-02-16,LABELING REVISIONS RELATED TO CLINICAL STUDIES
5014,0.25MG,REXULTI,OTSUKA,N,205422,2015-07-10,RX,TABLET,ORAL,2026-05-10,TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
5226,9MG,AUSTEDO,TEVA BRANDED PHARM,N,208082,2017-04-03,RX,TABLET,ORAL,2024-12-24,PEDIATRIC EXCLUSIVITY
4907,150MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2025-12-19,"MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY"
5516,5MG/0.5ML (5MG/0.5ML),MOUNJARO,ELI LILLY AND CO,N,215866,2022-05-13,RX,SOLUTION,SUBCUTANEOUS,2027-05-13,NEW CHEMICAL ENTITY
5154,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2027-03-19,"TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN"
836,EQ 7.8MG BASE;EQ 39.2MG BASE,AZSTARYS,COMMAVE THERAP,N,212994,2021-05-07,RX,CAPSULE,ORAL,2026-05-07,NEW CHEMICAL ENTITY
3578,EQ 150MG BASE,KRINTAFEL,GLAXOSMITHKLINE,N,210795,2018-07-20,RX,TABLET,ORAL,2023-07-20,NEW CHEMICAL ENTITY
5439,10MG,VERQUVO,MERCK SHARP DOHME,N,214377,2021-01-19,RX,TABLET,ORAL,2026-01-19,NEW CHEMICAL ENTITY
5297,15MG,VIZIMPRO,PFIZER,N,211288,2018-09-27,RX,TABLET,ORAL,2025-09-27,INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
5059,3MG,MULPLETA,SHIONOGI INC,N,210923,2018-07-31,RX,TABLET,ORAL,2023-07-31,NEW CHEMICAL ENTITY
4713,EQ 10MG BASE,XELJANZ,PF PRISM CV,N,203214,2018-05-30,RX,TABLET,ORAL,2024-12-14,"TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS, TO THE PRESCRIBING INFORMATION"
4329,EQ 30MG BASE/VIAL,SIGNIFOR LAR KIT,RECORDATI RARE,N,203255,2018-06-29,RX,FOR SUSPENSION,INTRAMUSCULAR,2025-06-29,INDICATED FOR TREATMENT OF PATIENTS WITH CUSHINGS DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
5342,EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL,RECARBRIO,MSD MERCK CO,N,212819,2019-07-16,RX,POWDER,INTRAVENOUS,2024-07-16,NEW CHEMICAL ENTITY
5244,50MG;20MG/PACKET,MAVYRET,ABBVIE,N,215110,2021-06-10,RX,PELLETS,ORAL,2028-06-10,"FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), B"
5358,EQ 21MG BASE,CAPLYTA,INTRA-CELLULAR,N,209500,2022-04-22,RX,CAPSULE,ORAL,2024-12-20,NEW CHEMICAL ENTITY
1539,100MG;300MG;300MG,DELSTRIGO,MSD MERCK CO,N,210807,2018-08-30,RX,TABLET,ORAL,2023-08-30,NEW CHEMICAL ENTITY
4811,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2027-09-19,PEDIATRIC EXCLUSIVITY
5154,150MG;37.5MG/PACKET,EPCLUSA,GILEAD SCIENCES INC,N,214187,2021-06-10,RX,PELLETS,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
5010,125MG/PACKET;100MG/PACKET,ORKAMBI,VERTEX PHARMS INC,N,211358,2018-08-07,RX,GRANULE,ORAL,2025-08-07,FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
4810,280MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2030-02-24,PEDIATRIC EXCLUSIVITY
4937,EQ 150MG BASE,ALECENSA,HOFFMANN-LA ROCHE,N,208434,2015-12-11,RX,CAPSULE,ORAL,2024-11-06,"FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB"
5390,13.5MG,PEMAZYRE,INCYTE CORP,N,213736,2020-04-17,RX,TABLET,ORAL,2029-08-26,TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
4575,40MG/5ML (8MG/ML),BLUDIGO,PROVEPHARM SAS,N,216264,2022-07-08,RX,SOLUTION,INTRAVENOUS,2027-07-08,NEW CHEMICAL ENTITY
4175,2.5MG;500MG,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2026-06-20,"REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST"
4188,1GM,FERRIPROX,CHIESI,N,021825,2019-07-25,RX,TABLET,ORAL,2028-04-30,TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
2552,EQ 0.2MG BASE/PACKET,PROGRAF,ASTELLAS,N,210115,2018-05-24,RX,FOR SUSPENSION,ORAL,2028-07-16,FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANT
5506,EQ 5MG BASE,PYRUKYND,AGIOS PHARMS INC,N,216196,2022-02-17,RX,TABLET,ORAL,2029-02-17,TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
4907,100MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2026-05-31,IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE FOR THETREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED (BRCAM) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
4903,EQ 100MG BASE,OFEV,BOEHRINGER INGELHEIM,N,205832,2014-10-15,RX,CAPSULE,ORAL,2023-03-09,TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
1053,EQ 20MG BASE,LEXAPRO,ABBVIE,N,021323,2002-08-14,RX,TABLET,ORAL,2026-05-12,NEW PATIENT POPULATION
4811,200MG/PACKET,SOVALDI,GILEAD SCIENCES INC,N,212480,2019-08-28,RX,PELLETS,ORAL,2026-08-28,FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
4811,150MG/PACKET,SOVALDI,GILEAD SCIENCES INC,N,212480,2019-08-28,RX,PELLETS,ORAL,2026-08-28,FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
5289,75MG,BRAFTOVI,ARRAY BIOPHARMA INC,N,210496,2018-06-27,RX,CAPSULE,ORAL,2023-04-08,"ENCORAFENIB, IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULTPATIENTS WITH METASTATIC COLORECTAL CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY"
4175,5MG,TRADJENTA,BOEHRINGER INGELHEIM,N,201280,2011-05-02,RX,TABLET,ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
5294,EQ 50MG BASE/VIAL,XERAVA,TETRAPHASE PHARMS,N,211109,2018-08-27,RX,POWDER,INTRAVENOUS,2028-08-27,GENERATING ANTIBIOTIC INCENTIVES NOW
4993,500MG;EQ 20MG BASE,VOQUEZNA DUAL PAK,PHATHOM,N,215153,2022-05-03,DISCN,"CAPSULE, TABLET",ORAL,2032-05-03,GENERATING ANTIBIOTIC INCENTIVES NOW
2806,49MG;51MG,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,2015-07-07,RX,TABLET,ORAL,2024-02-16,LABELING REVISIONS RELATED TO CLINICAL STUDIES
4468,EQ 28MG BASE,SPRAVATO,JANSSEN PHARMS,N,211243,2019-03-05,RX,SPRAY,NASAL,2023-07-31,TREATMENT OF SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD) WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR.
4802,EQ 1MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,DISCN,TABLET,ORAL,2025-12-22,PEDIATRIC EXCLUSIVITY
4359,EQ 400MG BASE,BOSULIF,PF PRISM CV,N,203341,2017-10-27,RX,TABLET,ORAL,2024-12-19,TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
5154,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2023-09-19,PEDIATRIC EXCLUSIVITY
4830,5MG;1GM,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,2015-08-26,RX,TABLET,ORAL,2026-06-20,NEW PATIENT POPULATION
2066,2MCG,ZEMPLAR,ABBVIE,N,021606,2005-05-26,RX,CAPSULE,ORAL,2023-10-18,INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4  AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
1076,99% (1ML),ABLYSINOL,BPI LABS,N,207987,2018-06-21,RX,SOLUTION,INTRA-ARTERIAL,2025-06-21,INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
2676,100MG,THIOLA EC,MISSION PHARMACAL CO,N,211843,2019-06-28,RX,"TABLET, DELAYED RELEASE",ORAL,2026-06-28,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5441,EQ 200MG BASE,UKONIQ,TG THERAPS,N,213176,2021-02-05,DISCN,TABLET,ORAL,2026-02-05,NEW CHEMICAL ENTITY
4188,80MG/ML,FERRIPROX,CHIESI,N,208030,2018-04-20,DISCN,SOLUTION,ORAL,2028-04-30,"TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011"
5446,20MG,PONVORY,JANSSEN PHARMS,N,213498,2021-03-18,RX,TABLET,ORAL,2026-03-18,NEW CHEMICAL ENTITY
776,EQ 50MG BASE/PACKET,PRADAXA,BOEHRINGER INGELHEIM,N,214358,2021-06-21,RX,PELLETS,ORAL,2024-06-21,NEW PRODUCT
4947,372MG,CRESEMBA,ASTELLAS,N,207501,2015-03-06,RX,POWDER,INTRAVENOUS,2025-03-06,GENERATING ANTIBIOTIC INCENTIVES NOW
4623,0.9%,NATROBA,PARAPRO LLC,N,022408,2011-01-18,RX,SUSPENSION,TOPICAL,2024-04-28,FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
5373,10ML,EXEM FOAM KIT,GISKIT,N,212279,2019-11-07,RX,FOAM,INTRAUTERINE,2024-11-07,NEW CHEMICAL ENTITY
3128,90MG,JADENU,NOVARTIS PHARMS CORP,N,206910,2015-03-30,RX,TABLET,ORAL,2023-07-23,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3
5289,50MG,BRAFTOVI,ARRAY BIOPHARMA INC,N,210496,2018-06-27,DISCN,CAPSULE,ORAL,2023-04-08,"ENCORAFENIB, IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULTPATIENTS WITH METASTATIC COLORECTAL CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY"
1076,99% (5ML),ABLYSINOL,BPI LABS,N,207987,2018-06-21,RX,SOLUTION,INTRA-ARTERIAL,2025-06-21,INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
4801,EQ 75MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2025-10-30,PEDIATRIC EXCLUSIVITY
2146,10%,PHENYLEPHRINE HYDROCHLORIDE,MANKIND PHARMA,A,216496,2023-01-11,RX,SOLUTION/DROPS,OPHTHALMIC,2023-07-17,COMPETITIVE GENERIC THERAPY
790,100MG;35MG,INQOVI,OTSUKA,N,212576,2020-07-07,RX,TABLET,ORAL,2027-07-07,"TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS."
4907,150MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2026-05-31,IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE FOR THETREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED (BRCAM) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
4275,EQ 10MG BASE/10ML (EQ 1MG BASE/ML),ZINC SULFATE,FRESENIUS KABI USA,A,216145,2022-12-27,RX,SOLUTION,INTRAVENOUS,2023-08-14,COMPETITIVE GENERIC THERAPY
4188,500MG,FERRIPROX,CHIESI,N,021825,2011-10-14,RX,TABLET,ORAL,2028-04-30,"TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011"
5218,EQ 200MG BASE,KISQALI,NOVARTIS,N,209092,2017-03-13,RX,TABLET,ORAL,2024-12-10,NEW PATIENT POPULATION
4554,0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,TRELEGY ELLIPTA,GLAXOSMITHKLINE,N,209482,2020-09-09,RX,POWDER,INHALATION,2023-09-09,NEW STRENGTH
5154,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
5407,0.75MG/ML,EVRYSDI,GENENTECH INC,N,213535,2020-08-07,RX,FOR SOLUTION,ORAL,2027-08-07,TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PATIENTS 2 MONTHS OF AGE AND OLDER
1932,EQ 50MG BASE,TASIGNA,NOVARTIS,N,022068,2018-03-22,RX,CAPSULE,ORAL,2029-03-23,PEDIATRIC EXCLUSIVITY
2480,250MG,DIACOMIT,BIOCODEX SA,N,206709,2018-08-20,RX,CAPSULE,ORAL,2025-08-20,INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
1593,EQ 0.18MG BASE,LUCEMYRA,USWM,N,209229,2018-05-16,RX,TABLET,ORAL,2023-05-16,NEW CHEMICAL ENTITY
5442,EQ 300MG BASE/VIAL,COSELA,G1 THERAP,N,214200,2021-02-12,RX,POWDER,INTRAVENOUS,2026-02-12,NEW CHEMICAL ENTITY
4190,EQ 20MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2028-09-22,TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
4182,1MG/ML,XARELTO,JANSSEN PHARMS,N,215859,2021-12-20,RX,FOR SUSPENSION,ORAL,2025-06-20,PEDIATRIC EXCLUSIVITY
4191,8MG,TOVIAZ,PFIZER,N,022030,2008-10-31,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-12-17,PEDIATRIC EXCLUSIVITY
4810,280MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2026-02-24,PEDIATRIC EXCLUSIVITY
2806,80MG,DIOVAN,NOVARTIS,N,021283,2001-07-18,RX,TABLET,ORAL,2024-04-19,NEW PATIENT POPULATION
2726,40MG/ML,XIPERE,BAUSCH AND LOMB INC,N,211950,2021-10-22,RX,SUSPENSION,INJECTION,2024-10-22,NEW PRODUCT
776,EQ 110MG BASE/PACKET,PRADAXA,BOEHRINGER INGELHEIM,N,214358,2021-06-21,RX,PELLETS,ORAL,2024-12-21,PEDIATRIC EXCLUSIVITY
4993,500MG;500MG;EQ 20MG BASE,VOQUEZNA TRIPLE PAK,PHATHOM,N,215152,2022-05-03,DISCN,"CAPSULE, TABLET, TABLET",ORAL,2032-05-03,GENERATING ANTIBIOTIC INCENTIVES NOW
4899,90MG;400MG,HARVONI,GILEAD SCIENCES INC,N,205834,2014-10-10,RX,TABLET,ORAL,2026-08-28,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5390,13.5MG,PEMAZYRE,INCYTE CORP,N,213736,2020-04-17,RX,TABLET,ORAL,2025-08-26,TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
5465,10MG,KERENDIA,BAYER HLTHCARE,N,215341,2021-07-09,RX,TABLET,ORAL,2025-09-01,INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF FIGARO-DKD STUDY
4942,EQ 10MG BASE,LENVIMA,EISAI INC,N,206947,2015-02-13,RX,CAPSULE,ORAL,2024-07-21,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
842,105MG;45MG,AUVELITY,AXSOME,N,215430,2022-08-18,RX,"TABLET, EXTENDED RELEASE",ORAL,2025-08-18,NEW PRODUCT
4483,30MG/VIAL,KYPROLIS,ONYX PHARMS AMGEN,N,202714,2016-06-03,RX,POWDER,INTRAVENOUS,2023-08-20,TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE
2406,EQ 20MG BASE,CRESTOR,IPR,N,021366,2003-08-12,RX,TABLET,ORAL,2023-05-27,"AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)"
5383,EQ 0.92MG BASE,ZEPOSIA,CELGENE INTL,N,209899,2020-03-25,RX,CAPSULE,ORAL,2025-03-25,NEW CHEMICAL ENTITY
1239,0.005MG/INH;0.05MG/INH,DULERA,ORGANON LLC,N,022518,2019-08-12,RX,"AEROSOL, METERED",INHALATION,2023-02-12,PEDIATRIC EXCLUSIVITY
852,5MG/SPRAY,VALTOCO,NEURELIS INC,N,211635,2020-01-10,RX,SPRAY,NASAL,2027-01-10,"INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT’S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER"
5280,EQ 100MG BASE,TAVALISSE,RIGEL PHARMS INC,N,209299,2018-04-17,RX,TABLET,ORAL,2023-04-17,NEW CHEMICAL ENTITY
4223,40MG,VIIBRYD,ABBVIE,N,022567,2011-01-21,RX,TABLET,ORAL,2023-01-31,INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
1725,500MG;EQ 50MG BASE,JANUMET,MSD SUB MERCK,N,022044,2007-03-30,RX,TABLET,ORAL,2024-06-04,PEDIATRIC EXCLUSIVITY
4483,60MG/VIAL,KYPROLIS,ONYX PHARMS AMGEN,N,202714,2012-07-20,RX,POWDER,INTRAVENOUS,2023-08-20,TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE
4190,EQ 5MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2026-05-24,TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
5390,4.5MG,PEMAZYRE,INCYTE CORP,N,213736,2020-04-17,RX,TABLET,ORAL,2029-08-26,TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
4310,100MG,VIMPAT,UCB INC,N,022253,2008-10-28,RX,TABLET,ORAL,2024-10-14,NEW PATIENT POPULATION
5516,7.5MG/0.5ML (7.5MG/0.5ML),MOUNJARO,ELI LILLY AND CO,N,215866,2022-05-13,RX,SOLUTION,SUBCUTANEOUS,2027-05-13,NEW CHEMICAL ENTITY
5402,100MG;35MG,INQOVI,OTSUKA,N,212576,2020-07-07,RX,TABLET,ORAL,2027-07-07,"TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS."
5296,25MG,COPIKTRA,SECURA,N,211155,2018-09-24,RX,CAPSULE,ORAL,2023-09-24,NEW CHEMICAL ENTITY
786,100MG;44MG,VYXEOS,CELATOR PHARMS,N,209401,2017-08-03,RX,POWDER,INTRAVENOUS,2024-03-30,NEW PATIENT POPULATION
5260,100MG,CALQUENCE,ASTRAZENECA,N,210259,2017-10-31,RX,CAPSULE,ORAL,2026-11-21,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
4816,0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,TRELEGY ELLIPTA,GLAXOSMITHKLINE,N,209482,2017-09-18,RX,POWDER,INHALATION,2023-09-09,MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
1725,500MG;EQ 50MG BASE,JANUMET XR,MERCK SHARP DOHME,N,202270,2012-02-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-02-12,PEDIATRIC EXCLUSIVITY
1709,1GM/VIAL;1GM/VIAL,VABOMERE,REMPEX,N,209776,2017-08-29,RX,POWDER,INTRAVENOUS,2022-08-29,NEW CHEMICAL ENTITY
4192,61MG,VYNDAMAX,FOLDRX PHARMS,N,212161,2019-05-03,RX,CAPSULE,ORAL,2026-05-03,TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
5393,80MG,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,2020-05-08,RX,CAPSULE,ORAL,2027-05-08,ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
4801,EQ 10MG BASE,TAFINLAR,NOVARTIS,N,217514,2023-03-16,RX,"TABLET, FOR SUSPENSION",ORAL,2026-03-16,NEW PRODUCT
2738,300MG,CUVRIOR,ORPHALAN,N,215760,2022-04-28,RX,TABLET,ORAL,2025-04-28,NEW PRODUCT
4810,560MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,DISCN,TABLET,ORAL,2030-02-24,PEDIATRIC EXCLUSIVITY
5470,EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML),KORSUVA,CARA THERAP,N,214916,2021-08-23,RX,SOLUTION,INTRAVENOUS,2026-08-23,NEW CHEMICAL ENTITY
5398,4MG/VIAL,ZEPZELCA,JAZZ,N,213702,2020-06-15,RX,POWDER,INTRAVENOUS,2027-06-15,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
4175,2.5MG;1GM,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
2066,1MCG,ZEMPLAR,ABBVIE,N,021606,2005-05-26,RX,CAPSULE,ORAL,2023-10-18,INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4  AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
760,0.1%,VERKAZIA,SANTEN,N,214965,2021-06-23,RX,EMULSION,OPHTHALMIC,2028-06-23,FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS
5014,1MG,REXULTI,OTSUKA,N,205422,2015-07-10,RX,TABLET,ORAL,2026-05-10,TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
4810,280MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2029-08-24,TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
1556,2.5MG;EQ 200MG BASE,KISQALI FEMARA CO-PACK (COPACKAGED),NOVARTIS,N,209935,2017-05-04,RX,TABLET,ORAL,2024-12-10,NEW PATIENT POPULATION
5446,5MG,PONVORY,JANSSEN PHARMS,N,213498,2021-03-18,RX,TABLET,ORAL,2026-03-18,NEW CHEMICAL ENTITY
4399,EQ 50MG ACID,PROMACTA,NOVARTIS,N,022291,2008-11-20,RX,TABLET,ORAL,2025-11-16,INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
4806,EQ 10MG BASE,TRINTELLIX,TAKEDA PHARMS USA,N,204447,2013-09-30,RX,TABLET,ORAL,2023-11-13,INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402
4188,1GM,FERRIPROX,CHIESI,N,212269,2020-05-19,RX,TABLET,ORAL,2024-04-30,TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
4802,EQ 0.5MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2025-04-30,"TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION"
5401,EQ 600MG BASE,RUKOBIA,VIIV HLTHCARE,N,212950,2020-07-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2025-07-02,NEW CHEMICAL ENTITY
3483,100MG,NOXAFIL,MERCK SHARP DOHME,N,205053,2013-11-25,RX,"TABLET, DELAYED RELEASE",ORAL,2028-06-17,FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
434,8MG/0.16ML (50MG/ML),BRIXADI,BRAEBURN,N,210136,2023-05-23,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2026-05-23,NEW PRODUCT
836,EQ 10.4MG BASE;EQ 52.3MG BASE,AZSTARYS,COMMAVE THERAP,N,212994,2021-05-07,RX,CAPSULE,ORAL,2026-05-07,NEW CHEMICAL ENTITY
852,7.5MG/SPRAY,VALTOCO,NEURELIS INC,N,211635,2020-01-10,RX,SPRAY,NASAL,2023-01-10,NEW PRODUCT
5384,EQ 1MG BASE,ISTURISA,RECORDATI RARE,N,212801,2020-03-06,RX,TABLET,ORAL,2025-03-06,NEW CHEMICAL ENTITY
5270,2.5MG;1GM,SEGLUROMET,MSD SUB MERCK,N,209806,2017-12-19,RX,TABLET,ORAL,2024-09-17,"REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV"
5429,,LOCAMETZ,AAA USA NOVARTIS,N,215841,2022-03-23,RX,POWDER,INTRAVENOUS,2025-03-23,NEW PRODUCT
24,3GM/PACKET; 1GM/PACKET,RELYVRIO,AMYLYX,N,216660,2022-09-29,RX,FOR SUSPENSION,ORAL,2029-09-29,TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
4811,400MG,SOVALDI,GILEAD SCIENCES INC,N,204671,2013-12-06,RX,TABLET,ORAL,2024-10-07,PEDIATRIC EXCLUSIVITY
5133,50MG,VENCLEXTA,ABBVIE,N,208573,2016-04-11,RX,TABLET,ORAL,2023-04-11,"TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
3317,2.5MG,REVLIMID,CELGENE,N,021880,2011-12-21,RX,CAPSULE,ORAL,2026-05-28,INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
5359,0.025%,TISSUEBLUE,DUTCH OPHTHALMIC,N,209569,2019-12-20,RX,SOLUTION,OPHTHALMIC,2026-12-20,INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)
5288,100MG/ML,EPIDIOLEX,GW RES LTD,N,210365,2018-09-28,RX,SOLUTION,ORAL,2027-07-31,TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER
5704,EQ 300MG BASE,SUNLENCA,GILEAD SCIENCES INC,N,215974,2022-12-22,RX,TABLET,ORAL,2027-12-22,NEW CHEMICAL ENTITY
5302,100MG,LORBRENA,PFIZER,N,210868,2018-11-02,RX,TABLET,ORAL,2024-03-03,EXPANDED INDICATION OF THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST
4820,4MG/ML,HETLIOZ LQ,VANDA PHARMS INC,N,214517,2020-12-01,RX,SUSPENSION,ORAL,2027-12-01,FOR THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PEDIATRIC PATIENTS 3 TO 15 YEARS OF AGE
4167,EQ 0.5MG BASE,FINGOLIMOD HYDROCHLORIDE,TEVA PHARMS USA,A,208008,2020-07-02,DISCN,CAPSULE,ORAL,2023-03-20,PATENT CHALLENGE
4329,EQ 60MG BASE/VIAL,SIGNIFOR LAR KIT,RECORDATI RARE,N,203255,2014-12-15,RX,FOR SUSPENSION,INTRAMUSCULAR,2025-06-29,INDICATED FOR TREATMENT OF PATIENTS WITH CUSHINGS DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
5390,9MG,PEMAZYRE,INCYTE CORP,N,213736,2020-04-17,RX,TABLET,ORAL,2027-04-17,"INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST"
559,EQ 0.5GM BASE;2GM/VIAL,AVYCAZ,ALLERGAN,N,206494,2015-02-25,RX,POWDER,INTRAVENOUS,2020-02-25,NEW CHEMICAL ENTITY
2448,1GM;EQ 50MG BASE,JANUMET,MSD SUB MERCK,N,022044,2007-03-30,RX,TABLET,ORAL,2023-12-04,ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
5396,30ML (8.1-51mCi/ML),TAUVID,AVID RADIOPHARMS INC,N,212123,2020-05-28,RX,SOLUTION,INTRAVENOUS,2025-05-28,NEW CHEMICAL ENTITY
4184,60MG,BRILINTA,ASTRAZENECA,N,022433,2015-09-03,RX,TABLET,ORAL,2023-05-28,TO REDUCE THE RISK OF A FIRST MYOCARDIAL INFARCTION (MI) OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) AT HIGH RISK FOR SUCH EVENTS
4907,100MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2025-03-11,FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY
841,9MG/9HR,XELSTRYM,NOVEN PHARMS INC,N,215401,2022-03-22,RX,SYSTEM,TRANSDERMAL,2025-03-22,NEW PRODUCT
1929,30MG,LAMPIT,BAYER HEALTHCARE,N,213464,2020-08-06,RX,TABLET,ORAL,2025-08-06,NEW CHEMICAL ENTITY
2967,EQ 0.85MG BASE/VIAL,TERLIVAZ,MALLINCKRODT IRELAND,N,022231,2022-09-14,RX,POWDER,INTRAVENOUS,2027-09-14,NEW CHEMICAL ENTITY
4811,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2023-03-19,NEW STRENGTH
5244,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
5133,10MG,VENCLEXTA,ABBVIE,N,208573,2016-04-11,RX,TABLET,ORAL,2023-04-11,"TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
2032,0.1%,UPNEEQ,RVL PHARMS,N,212520,2020-07-08,RX,SOLUTION/DROPS,OPHTHALMIC,2023-07-08,NEW PRODUCT
5291,200MG,TPOXX,SIGA TECHNOLOGIES,N,208627,2018-07-13,RX,CAPSULE,ORAL,2023-07-13,NEW CHEMICAL ENTITY
1963,1MG;0.5MG;40MG,MYFEMBREE,MYOVANT SCIENCES,N,214846,2021-05-26,RX,TABLET,ORAL,2026-01-27,INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF MVT-601-035
4810,560MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,DISCN,TABLET,ORAL,2023-05-06,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5267,0.25MG/0.5ML (0.25MG/0.5ML),WEGOVY,NOVO,N,215256,2021-06-04,RX,SOLUTION,SUBCUTANEOUS,2024-06-04,NEW PRODUCT
1534,10GM,PIZENSY,BRAINTREE LABS,N,211281,2020-02-12,DISCN,FOR SOLUTION,ORAL,2025-02-12,NEW CHEMICAL ENTITY
5511,15MG,CAMZYOS,BRISTOL,N,214998,2022-04-28,RX,CAPSULE,ORAL,2029-04-28,TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
5711,400MG,FILSPARI,TRAVERE,N,216403,2023-02-17,RX,TABLET,ORAL,2030-02-17,"TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN-TO-CREATININE RATIO (UPCR) > OR = 1.5 G/G"
1003,EQ 30MG BASE;120MG;EQ 15MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2021-10-07,RX,TABLET,ORAL,2028-10-07,A COMPLETE REGIMEN FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PEDIATRIC PATIENTS WEIGHING 14 KG TO LESS THAN 25 KG WHO HAVE NO ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF BIKTARVY
5301,20MG,XOFLUZA,GENENTECH INC,N,210854,2018-10-24,DISCN,TABLET,ORAL,2023-10-24,NEW CHEMICAL ENTITY
5709,50MG,JAYPIRCA,LOXO ONCOL,N,216059,2023-01-27,RX,TABLET,ORAL,2028-01-27,NEW CHEMICAL ENTITY
5398,4MG/VIAL,ZEPZELCA,JAZZ,N,213702,2020-06-15,RX,POWDER,INTRAVENOUS,2025-06-15,NEW CHEMICAL ENTITY
4799,0.05MG/INH;EQ 0.025MG BASE/INH,BREO ELLIPTA,GLAXO GRP LTD,N,204275,2023-05-12,RX,POWDER,INHALATION,2026-05-13,NEW STRENGTH
4947,74.5MG,CRESEMBA,ASTELLAS,N,207500,2022-11-22,RX,CAPSULE,ORAL,2027-03-06,GENERATING ANTIBIOTIC INCENTIVES NOW
4873,200MG,SIVEXTRO,CUBIST PHARMS LLC,N,205435,2014-06-20,RX,TABLET,ORAL,2019-06-20,NEW CHEMICAL ENTITY
5062,EQ 80MG BASE,TAGRISSO,ASTRAZENECA,N,208065,2015-11-13,RX,TABLET,ORAL,2023-12-18,"INDICATION OF OSIMERTINIB AS ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST"
5299,EQ 100MG BASE/VIAL,NUZYRA,PARATEK PHARMS INC,N,209817,2018-10-02,RX,POWDER,INTRAVENOUS,2023-10-02,NEW CHEMICAL ENTITY
5468,1.2MG,BYLVAY,ALBIREO,N,215498,2021-07-20,RX,CAPSULE,ORAL,2028-07-20,TREATMENT OF PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
5473,EQ 9.5MG BASE/ML,LIVMARLI,MIRUM,N,214662,2021-09-29,RX,SOLUTION,ORAL,2026-09-29,NEW CHEMICAL ENTITY
824,20MG,HEMADY,DEXCEL,N,211379,2019-10-03,RX,TABLET,ORAL,2026-10-03,INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
1413,500MG,ICOSAPENT ETHYL,TEVA PHARMS USA,A,209525,2020-09-11,RX,CAPSULE,ORAL,2023-03-08,PATENT CHALLENGE
4715,EQ 60MG BASE,CABOMETYX,EXELIXIS INC,N,208692,2016-04-25,RX,TABLET,ORAL,2028-09-17,THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
1225,0.055MG/INH,ARMONAIR RESPICLICK,TEVA PHARM,N,208798,2017-01-27,DISCN,POWDER,INHALATION,2025-01-09,PEDIATRIC EXCLUSIVITY
4171,1MG/2ML (0.5MG/ML),HALAVEN,EISAI INC,N,201532,2010-11-15,RX,SOLUTION,INTRAVENOUS,2023-01-28,TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLNE-CONTAINING REGIMEN
4174,400MG/2ML (200MG/ML);600MG/2ML (300MG/ML),CABENUVA KIT,VIIV HLTHCARE,N,212888,2021-01-21,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2026-01-21,NEW CHEMICAL ENTITY
4806,EQ 5MG BASE,TRINTELLIX,TAKEDA PHARMS USA,N,204447,2013-09-30,RX,TABLET,ORAL,2023-11-13,INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402
4318,EQ 30MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2025-10-07,PEDIATRIC EXCLUSIVITY
1150,EQ 2.2MG BASE/ML,FINTEPLA,UCB INC,N,212102,2020-06-25,RX,SOLUTION,ORAL,2027-06-25,INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
5300,EQ 0.1MG BASE,TALZENNA,PFIZER,N,211651,2023-06-20,RX,CAPSULE,ORAL,2023-10-16,NEW CHEMICAL ENTITY
1929,120MG,LAMPIT,BAYER HEALTHCARE,N,213464,2020-08-06,RX,TABLET,ORAL,2027-08-06,INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
1676,200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML),ZYNRELEF KIT,HERON THERAPS INC,N,211988,2021-05-12,RX,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2024-05-12,NEW PRODUCT
5446,10MG,PONVORY,JANSSEN PHARMS,N,213498,2021-03-18,RX,TABLET,ORAL,2026-03-18,NEW CHEMICAL ENTITY
5459,25MG,TRUSELTIQ,HELSINN HLTHCARE,N,214622,2021-05-28,DISCN,CAPSULE,ORAL,2028-05-28,"FOR TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST"
5319,EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML),TEGSEDI,AKCEA THERAPS,N,211172,2018-10-05,RX,SOLUTION,SUBCUTANEOUS,2023-10-05,NEW CHEMICAL ENTITY
2448,1GM;EQ 50MG BASE,JANUMET,MSD SUB MERCK,N,022044,2007-03-30,RX,TABLET,ORAL,2023-02-12,PEDIATRIC EXCLUSIVITY
5302,25MG,LORBRENA,PFIZER,N,210868,2018-11-02,RX,TABLET,ORAL,2025-11-02,INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
4355,140MG;125MG;125MG,"BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE",RICONPHARMA LLC,A,217511,2023-07-03,RX,CAPSULE,ORAL,2023-12-29,COMPETITIVE GENERIC THERAPY
5330,20MG,XPOVIO,KARYOPHARM THERAPS,N,212306,2019-07-03,RX,TABLET,ORAL,2023-06-22,"TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY"
2806,97MG;103MG,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,2015-07-07,RX,TABLET,ORAL,2024-02-16,LABELING REVISIONS RELATED TO CLINICAL STUDIES
2279,1.78GM,MILPROSA,FERRING PHARMS INC,N,201110,2020-04-29,DISCN,SYSTEM,VAGINAL,2023-04-29,NEW PRODUCT
4228,"80MG, 60MG, 40MG;59.5MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,217660,2023-04-26,RX,GRANULES,ORAL,2030-04-26,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 2 YEARS TO LESS THAN 6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
4182,2.5MG,XARELTO,JANSSEN PHARMS,N,022406,2018-10-11,RX,TABLET,ORAL,2025-02-23,PEDIATRIC EXCLUSIVITY
4806,EQ 20MG BASE,TRINTELLIX,TAKEDA PHARMS USA,N,204447,2013-09-30,RX,TABLET,ORAL,2023-11-13,INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402
4282,EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML),TRALEMENT,AM REGENT,N,209376,2020-07-02,RX,SOLUTION,INTRAVENOUS,2024-04-30,NEW CHEMICAL ENTITY
4304,10MG,FARXIGA,ASTRAZENECA AB,N,202293,2014-01-08,RX,TABLET,ORAL,2024-04-30,"TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION"
1725,12.5MG;500MG,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,2015-08-26,RX,TABLET,ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
1150,EQ 2.2MG BASE/ML,FINTEPLA,UCB INC,N,212102,2020-06-25,RX,SOLUTION,ORAL,2025-03-25,INDICATION FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) IN PATIENTS WHO ARE 2 YEARS OF AGE AND OLDER
4899,45MG;200MG,HARVONI,GILEAD SCIENCES INC,N,205834,2019-08-28,RX,TABLET,ORAL,2024-04-07,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
371,10MCG,DURYSTA,ABBVIE,N,211911,2020-03-04,RX,IMPLANT,OPHTHALMIC,2023-03-04,NEW PRODUCT
4741,EQ 20MG BASE,SIRTURO,JANSSEN THERAP,N,204384,2020-05-27,RX,TABLET,ORAL,2027-05-27,INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS 5 YEARS AND OLDER TO LESS THAN 12 YEARS OF AGE AND WEIGHING AT LEAST 15 KG WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
4634,14MG,TERIFLUNOMIDE,TEVA PHARMS USA,A,209700,2018-09-04,RX,TABLET,ORAL,2023-09-08,PATENT CHALLENGE
5358,EQ 42MG BASE,CAPLYTA,INTRA-CELLULAR,N,209500,2019-12-20,RX,CAPSULE,ORAL,2024-12-20,NEW CHEMICAL ENTITY
2808,EQ 0.03MG BASE/SPRAY,TYRVAYA,OYSTER POINT PHARMA,N,213978,2021-10-15,RX,SPRAY,NASAL,2024-10-15,NEW PRODUCT
5467,EQ 200MG BASE,REZUROCK,KADMON PHARMS LLC,N,214783,2021-07-16,RX,TABLET,ORAL,2028-07-16,TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
4188,1GM,FERRIPROX,CHIESI,N,021825,2019-07-25,RX,TABLET,ORAL,2024-04-30,TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
4188,500MG,FERRIPROX,CHIESI,N,021825,2011-10-14,RX,TABLET,ORAL,2024-04-30,TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
777,EQ 500MG BASE/VIAL,DALVANCE,ABBVIE,N,021883,2014-05-23,RX,POWDER,INTRAVENOUS,2024-07-22,NEW PATIENT POPULATION
5379,25MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2021-06-16,RX,TABLET,ORAL,2026-05-22,TREATMENT OF ADULT PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
785,80MG,SPRYCEL,BRISTOL MYERS SQUIBB,N,021986,2010-10-28,RX,TABLET,ORAL,2024-11-09,TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
1767,45MG,ADHANSIA XR,PURDUE PHARMA LP,N,212038,2019-02-27,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2024-06-28,LABELING REVISIONS RELATED TO CLINICAL STUDIES
5304,EQ 25MG BASE,DAURISMO,PFIZER,N,210656,2018-11-21,RX,TABLET,ORAL,2025-11-21,"INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >=75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY"
2134,100MG/VIAL,SEZABY,SUN PHARM INDS INC,N,215910,2022-11-17,RX,POWDER,INTRAVENOUS,2029-11-17,TREATMENT OF NEONATAL SEIZURES IN TERM AND PRETERM INFANTS
5283,EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL,AKYNZEO,HELSINN HLTHCARE,N,210493,2018-04-19,RX,POWDER,INTRAVENOUS,2023-04-19,NEW CHEMICAL ENTITY
5440,600MG/3ML (200MG/ML);900MG/3ML (300MG/ML),CABENUVA KIT,VIIV HLTHCARE,N,212888,2021-01-21,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2025-01-31,NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS
4811,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2023-09-19,PEDIATRIC EXCLUSIVITY
4185,240MG,ZELBORAF,HOFFMANN LA ROCHE,N,202429,2011-08-17,RX,TABLET,ORAL,2024-11-06,TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
4802,EQ 2MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2025-06-22,"TRAMETINIB IS INDICATED IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS"
4228,"100MG,75MG,50MG; 150MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2019-10-21,RX,TABLET,ORAL,2026-10-21,INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
5372,"80MG, 60MG, 40MG;59.5MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,217660,2023-04-26,RX,GRANULES,ORAL,2030-04-26,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 2 YEARS TO LESS THAN 6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
4802,EQ 2MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2025-10-30,PEDIATRIC EXCLUSIVITY
5295,100MG;300MG;300MG,DELSTRIGO,MSD MERCK CO,N,210807,2018-08-30,RX,TABLET,ORAL,2025-01-27,NEW PATIENT POPULATION
4810,70MG/ML,IMBRUVICA,PHARMACYCLICS LLC,N,217003,2022-08-24,RX,SUSPENSION,ORAL,2029-08-24,TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
4228,75MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2015-03-17,RX,GRANULE,ORAL,2025-08-15,THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
2608,100MG,KYZATREX,MARIUS PHARMS LLC,N,213953,2022-07-27,RX,CAPSULE,ORAL,2025-07-27,NEW PRODUCT
4228,75MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2015-03-17,RX,GRANULE,ORAL,2027-12-21,"FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS AND OLDER WHO HAVE ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020"
5372,"50MG,37.5MG,25MG; 75MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2021-06-08,RX,TABLET,ORAL,2024-10-21,NEW CHEMICAL ENTITY
4228,125MG;200MG,ORKAMBI,VERTEX PHARMS INC,N,206038,2015-07-02,RX,TABLET,ORAL,2023-09-28,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
192,500MG;500MG;EQ 20MG BASE,VOQUEZNA TRIPLE PAK,PHATHOM,N,215152,2022-05-03,DISCN,"CAPSULE, TABLET, TABLET",ORAL,2027-05-03,NEW CHEMICAL ENTITY
3302,55%,IODIXANOL,HENGRUI PHARMA,A,214271,2022-05-19,RX,INJECTABLE,INJECTION,2023-01-09,COMPETITIVE GENERIC THERAPY
5243,50MG;20MG/PACKET,MAVYRET,ABBVIE,N,215110,2021-06-10,RX,PELLETS,ORAL,2023-04-10,INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION
4713,EQ 5MG BASE,XELJANZ,PF PRISM CV,N,203214,2012-11-06,RX,TABLET,ORAL,2023-09-25,NEW PATIENT POPULATION
5679,3GM/PACKET; 1GM/PACKET,RELYVRIO,AMYLYX,N,216660,2022-09-29,RX,FOR SUSPENSION,ORAL,2029-09-29,TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
4944,EQ 30MG BASE;120MG;EQ 15MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2021-10-07,RX,TABLET,ORAL,2023-02-07,NEW CHEMICAL ENTITY
4318,EQ 30MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2023-10-15,PEDIATRIC EXCLUSIVITY
5014,0.5MG,REXULTI,OTSUKA,N,205422,2015-07-10,RX,TABLET,ORAL,2024-12-27,NEW PATIENT POPULATION
5297,15MG,VIZIMPRO,PFIZER,N,211288,2018-09-27,RX,TABLET,ORAL,2025-09-27,FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
5448,EQ 5.2MG BASE;EQ 26.1MG BASE,AZSTARYS,COMMAVE THERAP,N,212994,2021-05-07,RX,CAPSULE,ORAL,2026-05-07,NEW CHEMICAL ENTITY
5327,4MG,BALVERSA,JANSSEN BIOTECH,N,212018,2019-04-12,RX,TABLET,ORAL,2024-04-12,NEW CHEMICAL ENTITY
5358,EQ 10.5MG BASE,CAPLYTA,INTRA-CELLULAR,N,209500,2022-04-22,RX,CAPSULE,ORAL,2024-12-20,NEW CHEMICAL ENTITY
5416,EQ 10MG/ML BASE (EQ 10MG/ML BASE),IMCIVREE,RHYTHM,N,213793,2020-11-25,RX,SOLUTION,SUBCUTANEOUS,2025-06-16,CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGEAND OLDER WITH BARDET-BIEDL SYNDROME (BBS)
4899,33.75MG;150MG/PACKET,HARVONI,GILEAD SCIENCES INC,N,212477,2019-08-28,RX,PELLETS,ORAL,2026-08-28,"TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN"
4830,10MG,JARDIANCE,BOEHRINGER INGELHEIM,N,204629,2014-08-01,RX,TABLET,ORAL,2024-08-18,REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
2807,EQ 250MG BASE/5ML,VANCOMYCIN HYDROCHLORIDE,AMNEAL,A,215338,2023-06-23,RX,FOR SOLUTION,ORAL,2023-12-20,COMPETITIVE GENERIC THERAPY
2448,500MG;EQ 50MG BASE,JANUMET XR,MERCK SHARP DOHME,N,202270,2012-02-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-06-04,PEDIATRIC EXCLUSIVITY
5289,75MG,BRAFTOVI,ARRAY BIOPHARMA INC,N,210496,2018-06-27,RX,CAPSULE,ORAL,2023-06-27,NEW CHEMICAL ENTITY
793,36MG,EMFLAZA,PTC THERAP,N,208684,2017-02-09,RX,TABLET,ORAL,2026-06-07,TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
1802,EQ 50MG BASE/10ML (EQ 5MG BASE/ML),SEIZALAM,MMT,N,209566,2018-09-14,RX,SOLUTION,INTRAMUSCULAR,2025-09-14,TREATMENT OF STATUS EPILEPTICUS IN ADULTS
4143,800MG,DARUNAVIR,LUPIN LTD,A,202073,2022-09-29,RX,TABLET,ORAL,2023-11-28,PATENT CHALLENGE
5154,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2025-04-27,"UPDATES THE US PRESCRIBING INFORMATION WITH CLINICAL DATA REGARDING THE USE OF SOFOSBUVIR AND VELPATASVIR FOR THE TREATMENT OF CHRONIC HCV GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION IN PEOPLE WHO INJECT DRUGS (PWID), INCLUDING THOSE ON MEDICATION-ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER"
25,100MG/VIAL,VIDAZA,BRISTOL-MYERS,N,050794,2004-05-19,RX,POWDER,"INTRAVENOUS, SUBCUTANEOUS",2029-05-20,TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)
5506,EQ 5MG BASE,PYRUKYND,AGIOS PHARMS INC,N,216196,2022-02-17,RX,TABLET,ORAL,2027-02-17,NEW CHEMICAL ENTITY
4634,14MG,TERIFLUNOMIDE,SANDOZ,A,209710,2019-01-03,RX,TABLET,ORAL,2023-09-08,PATENT CHALLENGE
4746,1MG,POMALYST,BRISTOL,N,204026,2013-02-08,RX,CAPSULE,ORAL,2027-05-14,FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
5430,EQ 110MG BASE,ORLADEYO,BIOCRYST,N,214094,2020-12-03,RX,CAPSULE,ORAL,2027-12-03,PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
4820,20MG,TASIMELTEON,APOTEX,A,211607,2022-12-20,RX,CAPSULE,ORAL,2023-06-27,PATENT CHALLENGE
5379,25MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2021-06-16,RX,TABLET,ORAL,2028-06-16,"FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). ADVSM INCLUDES PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)"
4942,EQ 4MG BASE,LENVIMA,EISAI INC,N,206947,2015-02-13,RX,CAPSULE,ORAL,2025-08-15,INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
5411,4mL (1mCi/ML),DETECTNET,RADIOMEDIX,N,213227,2020-09-03,RX,SOLUTION,INTRAVENOUS,2025-09-03,NEW CHEMICAL ENTITY
5276,"150MG;150MG, 100MG",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,2018-02-12,RX,TABLET,ORAL,2026-06-21,TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
3578,EQ 150MG BASE,KRINTAFEL,GLAXOSMITHKLINE,N,210795,2018-07-20,RX,TABLET,ORAL,2025-07-20,INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
5389,150MG,TUKYSA,SEAGEN,N,213411,2020-04-17,RX,TABLET,ORAL,2027-04-17,"INDICATED FOR USE IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE FOR TREATMENT OF ADULT PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER AND BRAIN METASTASES, WHO HAVE RECEIVED ONE OR MORE PRIOR ANTI-HER2-BASED REGIMENS IN THE METASTIC SETTING"
5412,100MG,GAVRETO,GENENTECH INC,N,213721,2020-09-04,RX,CAPSULE,ORAL,2027-12-01,TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
4829,10MG,OTEZLA,AMGEN INC,N,205437,2014-03-21,RX,TABLET,ORAL,2023-04-10,INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
5511,10MG,CAMZYOS,BRISTOL,N,214998,2022-04-28,RX,CAPSULE,ORAL,2026-06-15,LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY MYK-461-017
5494,10MG,TAVNEOS,CHEMOCENTRYX,N,214487,2021-10-07,RX,CAPSULE,ORAL,2026-10-07,NEW CHEMICAL ENTITY
3317,20MG,LENALIDOMIDE,DR REDDYS,A,209348,2021-10-14,RX,CAPSULE,ORAL,2023-03-06,PATENT CHALLENGE
1225,0.03MG/INH,ARMONAIR RESPICLICK,TEVA PHARM,N,208798,2021-07-09,DISCN,POWDER,INHALATION,2024-07-09,NEW STRENGTH
5440,600MG/3ML (200MG/ML);900MG/3ML (300MG/ML),CABENUVA KIT,VIIV HLTHCARE,N,212888,2021-01-21,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2026-01-21,NEW CHEMICAL ENTITY
4810,70MG/ML,IMBRUVICA,PHARMACYCLICS LLC,N,217003,2022-08-24,RX,SUSPENSION,ORAL,2026-02-24,PEDIATRIC EXCLUSIVITY
4801,EQ 75MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2026-03-16,TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA WITH A BRAF V600 MUTATION WHO REQUIRE SYSTEMIC THERAPY
2720,EQ 0.125MG BASE,ORENITRAM,UNITED THERAP,N,203496,2013-12-20,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-10-18,INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
34,EQ 600MG BASE;EQ 50MG BASE;300MG,TRIUMEQ,VIIV HLTHCARE,N,205551,2014-08-22,RX,TABLET,ORAL,2026-06-15,INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY 205860
4745,1.1GM/ML,RAVICTI,HORIZON THERAP US,N,203284,2013-02-01,RX,LIQUID,ORAL,2024-04-28,FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS >=2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
2820,EQ 200MG BASE,QELBREE,SUPERNUS PHARMS,N,211964,2021-04-02,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-04-29,NEW PATIENT POPULATION
328,3%;0.1%,TWYNEO,GALDERMA LABS LP,N,214902,2021-07-26,RX,CREAM,TOPICAL,2024-07-26,NEW COMBINATION
4175,2.5MG;850MG,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
4182,20MG,XARELTO,JANSSEN PHARMS,N,022406,2011-11-04,RX,TABLET,ORAL,2024-08-23,"INDICATED TO REDUCE THE RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD, INCLUDING PATIENTS WHO HAVE RECENTLY UNDERGONE A LOWER EXTREMITY REVASCULARIZATION PROCEDURE DUE TO SYMPTOMATIC PAD"
4156,30MG/100ML (0.3MG/ML),RADICAVA,MITSUBISHI TANABE,N,209176,2017-05-05,RX,SOLUTION,INTRAVENOUS,2024-05-05,TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
5010,188MG/PACKET;150MG/PACKET,ORKAMBI,VERTEX PHARMS INC,N,211358,2018-08-07,RX,GRANULE,ORAL,2029-09-02,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 1 YEAR TO LESS THAN 2 YEARS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
5283,EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML),AKYNZEO,HELSINN HLTHCARE,N,210493,2020-05-27,RX,SOLUTION,INTRAVENOUS,2023-04-19,NEW CHEMICAL ENTITY
835,EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML),PRECEDEX,HOSPIRA,N,021038,1999-12-17,RX,INJECTABLE,INJECTION,2025-12-16,NEW PATIENT POPULATION
4899,90MG;400MG,HARVONI,GILEAD SCIENCES INC,N,205834,2014-10-10,RX,TABLET,ORAL,2024-10-07,PEDIATRIC EXCLUSIVITY
4811,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2027-03-19,"TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN"
4188,80MG/ML,FERRIPROX,CHIESI,N,208030,2018-04-20,DISCN,SOLUTION,ORAL,2028-04-30,TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
5421,6MG,JESDUVROQ,GLAXOSMITHKLINE,N,216951,2023-02-01,RX,TABLET,ORAL,2028-02-01,NEW CHEMICAL ENTITY
3300,25MG/VIAL,SPY AGENT GREEN KIT,NOVADAQ TECH,N,211580,2018-11-21,RX,POWDER,"INTRAVENOUS, INTERSTITIAL",2026-06-05,FOR FLUORESCENCE IMAGING OF LYMPH NODES AND DELINEATION OF LYMPHATIC VESSELS DURINGLYMPHATIC MAPPING IN ADULTS WITH BREAST CANCER FOR WHICH THIS PROCEDURE IS A COMPONENT OF INTRAOPERATIVEMANAGEMENT
5133,50MG,VENCLEXTA,ABBVIE,N,208573,2016-04-11,RX,TABLET,ORAL,2025-11-21,"INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY"
1530,EQ 19MCG BASE,ACUVUE THERAVISION WITH KETOTIFEN,JOHNSON JOHNSON VISN,N,022388,2022-02-25,DISCN,DRUG-ELUTING CONTACT LENS,OPHTHALMIC,2025-02-25,NEW PRODUCT
4811,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
4799,0.1MG/INH;EQ 0.025MG BASE/INH,BREO ELLIPTA,GLAXO GRP LTD,N,204275,2013-05-10,RX,POWDER,INHALATION,2026-05-13,NEW PATIENT POPULATION
5226,12MG,AUSTEDO,TEVA BRANDED PHARM,N,208082,2017-04-03,RX,TABLET,ORAL,2024-04-03,TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE
4187,250MG,XALKORI,PF PRISM CV,N,202570,2011-08-26,RX,CAPSULE,ORAL,2028-01-14,"TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE"
5379,100MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2025-01-09,NEW CHEMICAL ENTITY
770,100MG;44MG,VYXEOS,CELATOR PHARMS,N,209401,2017-08-03,RX,POWDER,INTRAVENOUS,2028-03-30,TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER
5709,100MG,JAYPIRCA,LOXO ONCOL,N,216059,2023-01-27,RX,TABLET,ORAL,2028-01-27,NEW CHEMICAL ENTITY
1725,2.5MG;1GM,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
935,40MG,BRONCHITOL,CHIESI,N,202049,2020-10-30,RX,POWDER,INHALATION,2023-10-30,NEW PRODUCT
4810,70MG/ML,IMBRUVICA,PHARMACYCLICS LLC,N,217003,2022-08-24,RX,SUSPENSION,ORAL,2025-08-24,NEW PRODUCT
4228,125MG;100MG,ORKAMBI,VERTEX PHARMS INC,N,206038,2016-09-28,RX,TABLET,ORAL,2023-09-28,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
4947,186MG,CRESEMBA,ASTELLAS,N,207500,2015-03-06,RX,CAPSULE,ORAL,2022-03-06,TREATMENT OF INVASIVE ASPERGILLOSIS
4228,5.8MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2023-05-03,RX,GRANULE,ORAL,2026-05-03,NEW PATIENT POPULATION
2140,EQ 15MG BASE;92MG,QSYMIA,VIVUS,N,022580,2012-07-17,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-06-24,NEW PATIENT POPULATION
2638,15MG/VIAL,TEPADINA,ADIENNE SA,N,208264,2017-01-26,RX,POWDER,"INTRACAVITARY, INTRAVENOUS, INTRAVESICAL",2024-01-26,INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
5286,2MG,MOXIDECTIN,MDGH,N,210867,2018-06-13,RX,TABLET,ORAL,2023-06-13,NEW CHEMICAL ENTITY
4283,EQ 50MG BASE,NUCYNTA,COLLEGIUM PHARM INC,N,022304,2008-11-20,RX,TABLET,ORAL,2026-07-03,NEW PATIENT POPULATION
5226,9MG,AUSTEDO,TEVA BRANDED PHARM,N,208082,2017-04-03,RX,TABLET,ORAL,2024-06-24,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
1725,500MG;EQ 50MG BASE,JANUMET,MSD SUB MERCK,N,022044,2007-03-30,RX,TABLET,ORAL,2023-12-04,ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
2480,250MG,DIACOMIT,BIOCODEX SA,N,206709,2018-08-20,RX,CAPSULE,ORAL,2023-08-20,NEW CHEMICAL ENTITY
5379,200MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2024-06-16,"TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) AND SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN)"
5372,"100MG,75MG,50MG; 150MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2019-10-21,RX,TABLET,ORAL,2028-06-08,FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 6 THROUGH 11 YEARS OLD WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
4290,0.225GM;0.188GM;1.479GM,SUTAB,BRAINTREE LABS,N,213135,2020-11-10,RX,TABLET,ORAL,2023-11-10,NEW PRODUCT
1725,2.5MG;850MG,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2026-06-20,"REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST"
4634,14MG,AUBAGIO,SANOFI AVENTIS US,N,202992,2012-09-12,RX,TABLET,ORAL,2024-10-30,PEDIATRIC EXCLUSIVITY
5348,EQ 600MG BASE,XENLETA,NABRIVA,N,211672,2019-08-19,RX,TABLET,ORAL,2024-08-19,NEW CHEMICAL ENTITY
5352,EQ 1GM BASE/VIAL,FETROJA,SHIONOGI INC,N,209445,2019-11-14,RX,POWDER,INTRAVENOUS,2029-11-14,GENERATING ANTIBIOTIC INCENTIVES NOW
5287,EQ 500MG BASE/10ML (EQ 50MG BASE/ML),ZEMDRI,CIPLA USA,N,210303,2018-06-25,RX,SOLUTION,INTRAVENOUS,2023-06-25,NEW CHEMICAL ENTITY
5267,1MG/0.5ML (1MG/0.5ML),WEGOVY,NOVO,N,215256,2021-06-04,RX,SOLUTION,SUBCUTANEOUS,2025-12-23,NEW PATIENT POPULATION
1932,EQ 50MG BASE,TASIGNA,NOVARTIS,N,022068,2018-03-22,RX,CAPSULE,ORAL,2025-03-22,TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
5380,EQ 200MG BASE,TAZVERIK,EPIZYME INC,N,211723,2020-01-23,RX,TABLET,ORAL,2023-06-18,TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
5504,50MG,CIBINQO,PFIZER,N,213871,2022-01-14,RX,TABLET,ORAL,2027-01-14,NEW CHEMICAL ENTITY
1003,200MG;EQ 25MG BASE,DESCOVY,GILEAD SCIENCES INC,N,208215,2016-04-04,RX,TABLET,ORAL,2024-09-28,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 35KG"
4715,EQ 60MG BASE,CABOMETYX,EXELIXIS INC,N,208692,2016-04-25,RX,TABLET,ORAL,2024-09-17,TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
5439,2.5MG,VERQUVO,MERCK SHARP DOHME,N,214377,2021-01-19,RX,TABLET,ORAL,2026-01-19,NEW CHEMICAL ENTITY
1003,EQ 50MG BASE;200MG;EQ 25MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2018-02-07,RX,TABLET,ORAL,2026-06-18,"FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF"
1798,EQ 50MG BASE/VIAL,MYCAMINE,ASTELLAS,N,021506,2005-03-16,RX,INJECTABLE,INTRAVENOUS,2023-06-20,PEDIATRIC EXCLUSIVITY
5068,50MG,BRIVIACT,UCB INC,N,205836,2016-05-12,RX,TABLET,ORAL,2024-08-27,NEW PATIENT POPULATION
5393,40MG,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,2020-05-08,RX,CAPSULE,ORAL,2029-09-21,"TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST"
2492,EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL,XACDURO (COPACKAGED),ENTASIS THERAP,N,216974,2023-05-23,RX,POWDER,INTRAVENOUS,2033-05-23,GENERATING ANTIBIOTIC INCENTIVES NOW
5495,EQ 40MG BASE,SCEMBLIX,NOVARTIS,N,215358,2021-10-29,RX,TABLET,ORAL,2026-10-29,NEW CHEMICAL ENTITY
4110,15MG,JYNARQUE,OTSUKA,N,204441,2018-04-23,RX,TABLET,ORAL,2025-04-23,INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
5440,400MG/2ML (200MG/ML);600MG/2ML (300MG/ML),CABENUVA KIT,VIIV HLTHCARE,N,212888,2021-01-21,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2026-01-21,NEW CHEMICAL ENTITY
5379,200MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2030-05-22,TREATMENT OF ADULT PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
1725,2.5MG;1GM,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,2012-01-30,RX,TABLET,ORAL,2023-03-30,ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5238,EQ 450MG BASE,BAXDELA,MELINTA,N,208610,2017-06-19,RX,TABLET,ORAL,2022-06-19,NEW CHEMICAL ENTITY
5360,10MG,DAYVIGO,EISAI INC,N,212028,2020-04-07,RX,TABLET,ORAL,2025-04-07,NEW CHEMICAL ENTITY
5465,20MG,KERENDIA,BAYER HLTHCARE,N,215341,2021-07-09,RX,TABLET,ORAL,2026-07-09,NEW CHEMICAL ENTITY
4156,105MG/5ML,RADICAVA ORS,MITSUBISHI TANABE,N,215446,2022-05-12,RX,SUSPENSION,ORAL,2025-05-12,NEW PRODUCT
5203,EQ 250MG BASE,RUBRACA,ZR PHARMA,N,209115,2017-05-01,RX,TABLET,ORAL,2025-04-06,"FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY"
5432,1MG;0.5MG;40MG,MYFEMBREE,MYOVANT SCIENCES,N,214846,2021-05-26,RX,TABLET,ORAL,2026-01-27,INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF MVT-601-035
5393,40MG,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,2020-05-08,RX,CAPSULE,ORAL,2029-09-21,TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
4899,45MG;200MG/PACKET,HARVONI,GILEAD SCIENCES INC,N,212477,2019-08-28,RX,PELLETS,ORAL,2026-08-28,"TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN"
5296,15MG,COPIKTRA,SECURA,N,211155,2018-09-24,RX,CAPSULE,ORAL,2023-09-24,NEW CHEMICAL ENTITY
4634,7MG,TERIFLUNOMIDE,GLENMARK PHARMS,A,209663,2018-11-15,RX,TABLET,ORAL,2023-09-08,PATENT CHALLENGE
5252,EQ 40MG BASE,NERLYNX,PUMA BIOTECH,N,208051,2017-07-17,RX,TABLET,ORAL,2024-06-28,NEW DOSING REGIMEN FOR THE PREVENTION AND MANAGEMENT OF NERATINIB‐ASSOCIATED DIARRHEA
4715,EQ 20MG BASE,CABOMETYX,EXELIXIS INC,N,208692,2016-04-25,RX,TABLET,ORAL,2024-01-22,"FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, AS A FIRST-LINE TREATMENT IN COMBINATION WITH NIVOLUMAB"
244,1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,TRISENOX,CEPHALON,N,021248,2000-09-25,DISCN,INJECTABLE,INJECTION,2025-01-12,ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
4283,EQ 75MG BASE,NUCYNTA,COLLEGIUM PHARM INC,N,022304,2008-11-20,RX,TABLET,ORAL,2026-07-03,NEW PATIENT POPULATION
5202,4MG,OLUMIANT,ELI LILLY AND CO,N,207924,2022-05-10,RX,TABLET,ORAL,2025-06-13,TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
4190,EQ 5MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2028-09-22,TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
4802,EQ 1MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,DISCN,TABLET,ORAL,2025-10-30,PEDIATRIC EXCLUSIVITY
4811,200MG;50MG/PACKET,EPCLUSA,GILEAD SCIENCES INC,N,214187,2021-06-10,RX,PELLETS,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
5203,EQ 200MG BASE,RUBRACA,ZR PHARMA,N,209115,2016-12-19,RX,TABLET,ORAL,2023-05-15,TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
1725,5MG;1GM,JENTADUETO XR,BOEHRINGER INGELHEIM,N,208026,2016-05-27,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-06-20,"REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST"
776,EQ 75MG BASE,PRADAXA,BOEHRINGER INGELHEIM,N,022512,2010-10-19,RX,CAPSULE,ORAL,2024-12-21,PEDIATRIC EXCLUSIVITY
4470,EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,EMEND,MERCK AND CO INC,N,022023,2008-01-25,DISCN,POWDER,INTRAVENOUS,2025-05-02,ADDITION OF A 3-DAY FOSAPREPITANT FOR INJECTION INTRAVENOUS DOSING REGIMEN IN PEDIATRIC PATIENTS FOR THE CURRENTLY APPROVED PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
4810,70MG,IMBRUVICA,PHARMACYCLICS LLC,N,205552,2017-12-20,RX,CAPSULE,ORAL,2026-02-24,PEDIATRIC EXCLUSIVITY
5262,480MG,PREVYMIS,MERCK SHARP DOHME,N,209939,2017-11-08,RX,TABLET,ORAL,2030-06-05,FOR PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
4184,90MG,BRILINTA,ASTRAZENECA,N,022433,2011-07-20,RX,TABLET,ORAL,2023-11-28,PEDIATRIC EXCLUSIVITY
4811,45MG;200MG,HARVONI,GILEAD SCIENCES INC,N,205834,2019-08-28,RX,TABLET,ORAL,2024-10-07,PEDIATRIC EXCLUSIVITY
5302,25MG,LORBRENA,PFIZER,N,210868,2018-11-02,RX,TABLET,ORAL,2028-03-03,"TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST, EXCLUDING PATIENTS WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB OR CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE"
5270,5MG;EQ 100MG BASE,STEGLUJAN,MSD SUB MERCK,N,209805,2017-12-19,RX,TABLET,ORAL,2024-09-17,"REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV"
5379,50MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2021-06-16,RX,TABLET,ORAL,2025-01-09,NEW CHEMICAL ENTITY
5259,200MG,VERZENIO,ELI LILLY AND CO,N,208716,2017-09-28,RX,TABLET,ORAL,2024-10-12,"INDICATION FOR THE USE OF ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, NODE-POSITIVE, EARLY CANCER (EBC) AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE>20% AS DETERMINED BY AN FDA APPROVED TEST"
4318,EQ 20MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2023-04-15,"TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY"
5267,0.5MG/0.5ML (0.5MG/0.5ML),WEGOVY,NOVO,N,215256,2021-06-04,RX,SOLUTION,SUBCUTANEOUS,2024-06-04,NEW PRODUCT
5012,49MG;51MG,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,2015-07-07,RX,TABLET,ORAL,2024-02-16,LABELING REVISIONS RELATED TO CLINICAL STUDIES
4805,EQ 60MG BASE;EQ 5MG BASE;30MG,TRIUMEQ PD,VIIV HLTHCARE,N,215413,2022-03-30,RX,"TABLET, FOR SUSPENSION",ORAL,2026-12-15,PEDIATRIC EXCLUSIVITY
4182,2.5MG,XARELTO,JANSSEN PHARMS,N,022406,2018-10-11,RX,TABLET,ORAL,2023-04-11,PEDIATRIC EXCLUSIVITY
5048,EQ 17.8MG BASE,WAKIX,HARMONY,N,211150,2019-08-14,RX,TABLET,ORAL,2023-10-13,TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
5468,0.4MG,BYLVAY,ALBIREO,N,215498,2021-07-20,RX,CAPSULE,ORAL,2028-07-20,TREATMENT OF PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
4907,150MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2024-08-17,"MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY"
5014,4MG,REXULTI,OTSUKA,N,205422,2015-07-10,RX,TABLET,ORAL,2024-12-27,NEW PATIENT POPULATION
4899,90MG;400MG,HARVONI,GILEAD SCIENCES INC,N,205834,2014-10-10,RX,TABLET,ORAL,2024-04-07,"TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS"
2480,250MG/PACKET,DIACOMIT,BIOCODEX SA,N,207223,2018-08-20,RX,FOR SUSPENSION,ORAL,2025-07-14,NEW PATIENT POPULATION
432,300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML),ZYNRELEF KIT,HERON THERAPS INC,N,211988,2021-05-12,DISCN,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2024-05-12,NEW PRODUCT
2552,EQ 5MG BASE,PROGRAF,ASTELLAS,N,050708,1994-04-08,RX,CAPSULE,ORAL,2025-05-24,"PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY OR HEART TRANSPLANTS, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS"
5430,EQ 150MG BASE,ORLADEYO,BIOCRYST,N,214094,2020-12-03,RX,CAPSULE,ORAL,2027-12-03,PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
5379,50MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2021-06-16,RX,TABLET,ORAL,2028-06-16,"FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). ADVSM INCLUDES PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)"
5202,2MG,OLUMIANT,ELI LILLY AND CO,N,207924,2018-05-31,RX,TABLET,ORAL,2025-05-10,"TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)"
5457,1080MG/20ML (54MG/ML),EMPAVELI,APELLIS PHARMS,N,215014,2021-05-14,RX,SOLUTION,SUBCUTANEOUS,2026-02-08,INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF STUDY APL2-308
1539,EQ 60MG BASE;EQ 5MG BASE;30MG,TRIUMEQ PD,VIIV HLTHCARE,N,215413,2022-03-30,RX,"TABLET, FOR SUSPENSION",ORAL,2026-06-15,NEW PATIENT POPULATION
4820,20MG,HETLIOZ,VANDA PHARMS INC,N,205677,2014-01-31,RX,CAPSULE,ORAL,2027-12-01,THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
4810,280MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2023-05-06,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
4944,EQ 50MG BASE;200MG;EQ 25MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2018-02-07,RX,TABLET,ORAL,2023-02-07,NEW CHEMICAL ENTITY
4382,25MG,MYRBETRIQ,APGDI,N,202611,2012-06-28,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-09-25,PEDIATRIC EXCLUSIVITY
5681,7.2765GM/15ML (485.1MG/ML),ELUCIREM,GUERBET,N,216986,2022-09-21,RX,SOLUTION,INTRAVENOUS,2027-09-21,NEW CHEMICAL ENTITY
4907,150MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2023-05-19,TX OF ADULT PTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
776,EQ 150MG BASE,PRADAXA,BOEHRINGER INGELHEIM,N,022512,2010-10-19,RX,CAPSULE,ORAL,2024-12-21,PEDIATRIC EXCLUSIVITY
5328,50MG,PIQRAY,NOVARTIS,N,212526,2019-05-24,RX,TABLET,ORAL,2024-05-24,NEW CHEMICAL ENTITY
4174,400MG/2ML (200MG/ML);600MG/2ML (300MG/ML),CABENUVA KIT,VIIV HLTHCARE,N,212888,2021-01-21,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2025-01-31,NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS
5388,EQ 25MG BASE,KOSELUGO,ASTRAZENECA,N,213756,2020-04-10,RX,CAPSULE,ORAL,2025-04-10,NEW CHEMICAL ENTITY
972,EQ 30MG BASE,CYMBALTA,LILLY,N,021427,2004-08-03,RX,"CAPSULE, DELAYED REL PELLETS",ORAL,2023-04-20,NEW PATIENT POPULATION
2245,5MG,PREDNISOLONE,AUROBINDO PHARMA LTD,A,215673,2023-03-17,RX,TABLET,ORAL,2023-11-18,COMPETITIVE GENERIC THERAPY
785,20MG,SPRYCEL,BRISTOL MYERS SQUIBB,N,021986,2006-06-28,RX,TABLET,ORAL,2024-11-09,TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
3531,500MCG,ROFLUMILAST,MYLAN,A,208257,2018-07-13,RX,TABLET,ORAL,2023-04-17,PATENT CHALLENGE
4944,EQ 50MG BASE;200MG;EQ 25MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2018-02-07,RX,TABLET,ORAL,2024-02-24,LABELING REVISIONS RELATED TO CLINICAL STUDIES
4566,6GM/PACKET,LUMRYZ,AVADEL CNS,N,214755,2023-05-01,RX,"FOR SUSPENSION, EXTENDED RELEASE",ORAL,2026-05-01,NEW PRODUCT
4228,150MG,KALYDECO,VERTEX PHARMS,N,203188,2012-01-31,RX,TABLET,ORAL,2024-05-17,"TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N"
4678,EQ 1.2GM BASE/VIAL,KIMYRSA,MELINTA THERAP,N,214155,2021-03-12,RX,POWDER,INTRAVENOUS,2024-03-12,NEW PRODUCT
2608,150MG,KYZATREX,MARIUS PHARMS LLC,N,213953,2022-07-27,RX,CAPSULE,ORAL,2025-07-27,NEW PRODUCT
4228,"80MG, 60MG, 40MG;59.5MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,217660,2023-04-26,RX,GRANULES,ORAL,2026-04-26,NEW PRODUCT
4182,15MG,XARELTO,JANSSEN PHARMS,N,022406,2011-11-04,RX,TABLET,ORAL,2025-02-23,PEDIATRIC EXCLUSIVITY
4228,94MG/PACKET;75MG/PACKET,ORKAMBI,VERTEX PHARMS INC,N,211358,2022-09-02,RX,GRANULE,ORAL,2025-09-02,NEW STRENGTH
5461,320MG,LUMAKRAS,AMGEN INC,N,214665,2023-01-20,RX,TABLET,ORAL,2026-05-28,NEW CHEMICAL ENTITY
4310,100MG,VIMPAT,UCB INC,N,022253,2008-10-28,RX,TABLET,ORAL,2023-11-16,ADDITION OF A NEW INDICATION FOR ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
5390,4.5MG,PEMAZYRE,INCYTE CORP,N,213736,2020-04-17,RX,TABLET,ORAL,2025-08-26,TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
4944,EQ 50MG BASE;200MG;EQ 25MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2018-02-07,RX,TABLET,ORAL,2026-06-18,"FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF"
5379,300MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2027-01-09,"INDICATED FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC GIST HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION, INCLUDING PDGFRA D842V MUTATIONS"
5480,0.4MG/VIAL,VOXZOGO,BIOMARIN PHARM,N,214938,2021-11-19,RX,POWDER,SUBCUTANEOUS,2028-11-19,TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
1125,180MG;10MG,NEXLIZET,ESPERION THERAPS INC,N,211617,2020-02-26,RX,TABLET,ORAL,2023-02-26,NEW PRODUCT
1003,EQ 50MG BASE;200MG;EQ 25MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2018-02-07,RX,TABLET,ORAL,2023-02-07,NEW CHEMICAL ENTITY
1426,EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL,RECARBRIO,MSD MERCK CO,N,212819,2019-07-16,RX,POWDER,INTRAVENOUS,2029-07-16,GENERATING ANTIBIOTIC INCENTIVES NOW
4190,EQ 25MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2025-12-19,REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
5709,50MG,JAYPIRCA,LOXO ONCOL,N,216059,2023-01-27,RX,TABLET,ORAL,2030-01-27,"TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR"
5190,2GM/VIAL,STERITALC,NOVATECH SA,N,205555,2017-05-01,RX,POWDER,INTRAPLEURAL,2024-05-01,TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
5681,24.255GM/50ML (485.1MG/ML),ELUCIREM,GUERBET,N,216986,2022-09-21,RX,SOLUTION,INTRAVENOUS,2027-09-21,NEW CHEMICAL ENTITY
1802,50MG/50ML (1MG/ML),MIDAZOLAM IN 0.9% SODIUM CHLORIDE,HIKMA,A,216159,2023-04-17,RX,SOLUTION,INTRAVENOUS,2024-01-02,PATENT CHALLENGE
4746,3MG,POMALYST,BRISTOL,N,204026,2013-02-08,RX,CAPSULE,ORAL,2024-05-20,PEDIATRIC EXCLUSIVITY
4907,100MG,LYNPARZA,ASTRAZENECA,N,208558,2017-08-17,RX,TABLET,ORAL,2024-08-17,TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
852,10MG/SPRAY,VALTOCO,NEURELIS INC,N,211635,2020-01-10,RX,SPRAY,NASAL,2023-01-10,NEW PRODUCT
1725,1GM;EQ 50MG BASE,JANUMET XR,MERCK SHARP DOHME,N,202270,2012-02-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-12-04,ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
4336,EQ 10MG BASE,FIRDAPSE,CATALYST PHARMS,N,208078,2018-11-28,RX,TABLET,ORAL,2025-09-29,NEW PATIENT POPULATION
3483,300MG/16.7ML (18MG/ML),POSACONAZOLE,PAR STERILE PRODUCTS,A,208768,2022-05-25,RX,SOLUTION,INTRAVENOUS,2023-12-26,PATENT CHALLENGE
4566,0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML,XYWAV,JAZZ,N,212690,2020-07-21,RX,SOLUTION,ORAL,2027-07-21,INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
419,4MG,TARPEYO,CALLIDITAS,N,215935,2021-12-15,RX,"CAPSULE, DELAYED RELEASE",ORAL,2024-12-15,NEW PRODUCT
5313,EQ 10MG BASE/5ML (EQ 2MG BASE/ML),ONPATTRO,ALNYLAM PHARMS INC,N,210922,2018-08-10,RX,SOLUTION,INTRAVENOUS,2025-08-10,INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
4829,30MG,OTEZLA,AMGEN INC,N,205437,2014-03-21,RX,TABLET,ORAL,2023-04-10,INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
5459,100MG,TRUSELTIQ,HELSINN HLTHCARE,N,214622,2021-05-28,DISCN,CAPSULE,ORAL,2028-05-28,"FOR TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST"
1751,EQ 2.5MG BASE/ML,XATMEP,AZURITY,N,208400,2017-04-25,RX,SOLUTION,ORAL,2024-04-25,"TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS"
5014,0.25MG,REXULTI,OTSUKA,N,205422,2015-07-10,RX,TABLET,ORAL,2024-12-27,NEW PATIENT POPULATION
4715,EQ 60MG BASE,CABOMETYX,EXELIXIS INC,N,208692,2016-04-25,RX,TABLET,ORAL,2026-01-14,INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
4802,EQ 0.5MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2025-05-04,"TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS"
1150,EQ 2.2MG BASE/ML,FINTEPLA,UCB INC,N,212102,2020-06-25,RX,SOLUTION,ORAL,2023-12-25,PEDIATRIC EXCLUSIVITY
5457,1080MG/20ML (54MG/ML),EMPAVELI,APELLIS PHARMS,N,215014,2021-05-14,RX,SOLUTION,SUBCUTANEOUS,2026-05-14,NEW CHEMICAL ENTITY
5233,30MG,ALUNBRIG,TAKEDA PHARMS USA,N,208772,2017-04-28,RX,TABLET,ORAL,2023-05-22,EXPANDED INDICATION OF THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST
4899,45MG;200MG,HARVONI,GILEAD SCIENCES INC,N,205834,2019-08-28,RX,TABLET,ORAL,2026-08-28,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5416,EQ 10MG/ML BASE (EQ 10MG/ML BASE),IMCIVREE,RHYTHM,N,213793,2020-11-25,RX,SOLUTION,SUBCUTANEOUS,2029-06-16,FOR CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH MONOGENIC OR SYNDROMIC OBESITY DUE TO BARDET-BIEDL SYNDROME (BBS)
668,500MG;500MG;EQ 20MG BASE,VOQUEZNA TRIPLE PAK,PHATHOM,N,215152,2022-05-03,DISCN,"CAPSULE, TABLET, TABLET",ORAL,2027-05-03,NEW CHEMICAL ENTITY
824,2MG,DEXAMETHASONE,AMNEAL,A,216295,2022-09-08,RX,TABLET,ORAL,2023-03-08,COMPETITIVE GENERIC THERAPY
1123,2MG/VIAL,BYDUREON,ASTRAZENECA AB,N,022200,2012-01-27,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2024-07-22,NEW PATIENT POPULATION
4836,16MG,SCENESSE,CLIVUNEL INC,N,210797,2019-10-08,RX,IMPLANT,SUBCUTANEOUS,2026-10-08,INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
785,70MG,SPRYCEL,BRISTOL MYERS SQUIBB,N,021986,2006-06-28,RX,TABLET,ORAL,2025-05-09,PEDIATRIC EXCLUSIVITY
4228,75MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2015-03-17,RX,GRANULE,ORAL,2026-04-29,TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
4283,EQ 100MG BASE,NUCYNTA,COLLEGIUM PHARM INC,N,022304,2008-11-20,RX,TABLET,ORAL,2026-07-03,NEW PATIENT POPULATION
4190,EQ 1.5% BASE,OPZELURA,INCYTE CORP,N,215309,2021-09-21,RX,CREAM,TOPICAL,2024-09-21,NEW PRODUCT
5416,EQ 10MG/ML BASE (EQ 10MG/ML BASE),IMCIVREE,RHYTHM,N,213793,2020-11-25,RX,SOLUTION,SUBCUTANEOUS,2025-11-25,NEW CHEMICAL ENTITY
5376,100MG/20ML (5MG/ML),VEKLURY,GILEAD SCIENCES INC,N,214787,2020-10-22,RX,SOLUTION,INTRAVENOUS,2025-01-21,"3-DAY DOSING REGIMEN FOR THE TREATMENT OF COVID-19 IN ADULTS AND PEDIATRIC PATIENTS (>12 YEARS AND WEIGHING AT LEAST 40 KG) WITH POSITIVE RESULTS OF DIRECT SARS-COV-2 VIRAL TESTING, WHO ARE NOT HOSPITALIZED AND HAVE MILD-TO-MODERATE COVID-19, AND ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH"
5267,1.7MG/0.75ML (1.7MG/0.75ML),WEGOVY,NOVO,N,215256,2021-06-04,RX,SOLUTION,SUBCUTANEOUS,2025-12-23,NEW PATIENT POPULATION
4228,"50MG,37.5MG,25MG; 75MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2021-06-08,RX,TABLET,ORAL,2024-10-21,NEW CHEMICAL ENTITY
4881,5MG,BELSOMRA,MERCK SHARP DOHME,N,204569,2014-08-13,RX,TABLET,ORAL,2023-01-29,"INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE"
5440,EQ 30MG BASE,VOCABRIA,VIIV HLTHCARE,N,212887,2021-01-21,RX,TABLET,ORAL,2026-01-21,NEW CHEMICAL ENTITY
2706,EQ 15MG BASE;92MG,QSYMIA,VIVUS,N,022580,2012-07-17,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-06-24,NEW PATIENT POPULATION
5732,50ML (8-158mCi/ML),POSLUMA,BLUE EARTH,N,216023,2023-05-25,RX,SOLUTION,INTRAVENOUS,2028-05-25,NEW CHEMICAL ENTITY
466,3MCG/GM,VECTICAL,GALDERMA LABS LP,N,022087,2009-01-23,RX,OINTMENT,TOPICAL,2023-07-17,NEW PATIENT POPULATION
5292,250MG,TIBSOVO,SERVIER,N,211192,2018-07-20,RX,TABLET,ORAL,2024-08-25,"FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST"
5218,2.5MG;EQ 200MG BASE,KISQALI FEMARA CO-PACK (COPACKAGED),NOVARTIS,N,209935,2017-05-04,RX,TABLET,ORAL,2024-12-10,NEW PATIENT POPULATION
1725,12.5MG;1GM,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,2016-12-09,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-06-20,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
2448,500MG;EQ 50MG BASE,JANUMET,MSD SUB MERCK,N,022044,2007-03-30,RX,TABLET,ORAL,2023-02-12,PEDIATRIC EXCLUSIVITY
768,EQ 0.37% BASE,CYSTADROPS,RECORDATI RARE,N,211302,2020-08-19,RX,SOLUTION/DROPS,OPHTHALMIC,2023-08-19,NEW PRODUCT
5415,EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE),OXLUMO,ALNYLAM PHARMS INC,N,214103,2020-11-23,RX,SOLUTION,SUBCUTANEOUS,2027-11-23,TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER URINARY OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
2441,EQ 10MG BASE/ML,REVATIO,VIATRIS,N,203109,2012-08-30,RX,FOR SUSPENSION,ORAL,2026-01-31,LABELING REGARDING NEW DOSING REGIMEN IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND TREATMENT OF PAH IN PEDIATRIC PATIENTS (AGES 1-17)
4810,140MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2025-08-24,NEW PATIENT POPULATION
4399,EQ 25MG ACID/PACKET,PROMACTA KIT,NOVARTIS,N,207027,2015-08-24,RX,FOR SUSPENSION,ORAL,2025-11-16,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5297,15MG,VIZIMPRO,PFIZER,N,211288,2018-09-27,RX,TABLET,ORAL,2023-09-27,NEW CHEMICAL ENTITY
4190,EQ 15MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2026-05-24,TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
4290,0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT,SUFLAVE,BRAINTREE LABS,N,215344,2023-06-15,RX,FOR SOLUTION,ORAL,2026-06-15,NEW PRODUCT
5393,80MG,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,2020-05-08,RX,CAPSULE,ORAL,2025-05-08,NEW CHEMICAL ENTITY
2743,EQ 8.19MG BASE;20MG,LONSURF,TAIHO ONCOLOGY,N,207981,2015-09-22,RX,TABLET,ORAL,2026-02-22,"TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY"
5012,49MG;51MG,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,2015-07-07,RX,TABLET,ORAL,2023-04-01,PEDIATRIC EXCLUSIVITY
5394,50MG,QINLOCK,DECIPHERA PHARMS,N,213973,2020-05-15,RX,TABLET,ORAL,2027-05-15,"INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB"
5520,300MG;100MG,PAXLOVID (COPACKAGED),PFIZER,N,217188,2023-05-25,RX,TABLET,ORAL,2028-05-25,NEW CHEMICAL ENTITY
1963,1MG;0.5MG;40MG,MYFEMBREE,MYOVANT SCIENCES,N,214846,2021-05-26,RX,TABLET,ORAL,2024-05-26,NEW PRODUCT
4228,13.4MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2023-05-03,RX,GRANULE,ORAL,2030-05-03,THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS 1 MONTH TO LESS THAN 4 MONTHS OF AGE WHO HAVE AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
4199,0.225GM;0.188GM;1.479GM,SUTAB,BRAINTREE LABS,N,213135,2020-11-10,RX,TABLET,ORAL,2023-11-10,NEW PRODUCT
1678,EQ 50MG BASE/VIAL,EVOMELA,ACROTECH BIOPHARMA,N,207155,2016-03-10,RX,POWDER,INTRAVENOUS,2023-03-10,FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
5302,100MG,LORBRENA,PFIZER,N,210868,2018-11-02,RX,TABLET,ORAL,2025-11-02,INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
5324,100MG/20ML (5MG/ML),ZULRESSO,SAGE THERAP,N,211371,2019-06-17,RX,SOLUTION,INTRAVENOUS,2024-06-17,NEW CHEMICAL ENTITY
4811,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2028-12-10,PEDIATRIC EXCLUSIVITY
776,EQ 40MG BASE/PACKET,PRADAXA,BOEHRINGER INGELHEIM,N,214358,2021-06-21,RX,PELLETS,ORAL,2024-12-21,PEDIATRIC EXCLUSIVITY
5383,EQ 0.46MG BASE,ZEPOSIA,CELGENE INTL,N,209899,2020-03-25,RX,CAPSULE,ORAL,2024-05-27,FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS
5445,EQ 20MG BASE/VIAL,PEPAXTO,ONCOPEPTIDES AB,N,214383,2021-02-26,DISCN,POWDER,INTRAVENOUS,2028-02-26,"TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OF THERAPY AND WHOSE DISEASE IS REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT, AND ONE CD-38 DIRECTED MONOCLONAL ANTIBODY"
4228,75MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2015-03-17,RX,GRANULE,ORAL,2024-05-17,"TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N"
2419,0.055MG/INH;EQ 0.014MG BASE/INH,AIRDUO RESPICLICK,TEVA PHARM,N,208799,2017-01-27,RX,POWDER,INHALATION,2025-01-09,PEDIATRIC EXCLUSIVITY
4881,10MG,BELSOMRA,MERCK SHARP DOHME,N,204569,2014-08-13,RX,TABLET,ORAL,2023-01-29,"INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE"
4716,EQ 30MG BASE,ICLUSIG,TAKEDA PHARMS USA,N,203469,2015-04-23,RX,TABLET,ORAL,2023-12-18,CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS
568,56MG;44MG,SEGLENTIS,KOWA PHARMS,N,213426,2021-10-15,RX,TABLET,ORAL,2024-10-15,NEW PRODUCT
2046,EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL,AKYNZEO,HELSINN HLTHCARE,N,210493,2018-04-19,RX,POWDER,INTRAVENOUS,2023-04-19,NEW CHEMICAL ENTITY
4187,250MG,XALKORI,PF PRISM CV,N,202570,2011-08-26,RX,CAPSULE,ORAL,2024-01-14,"TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE"
5353,80MG,BRUKINSA,BEIGENE,N,213217,2019-11-14,RX,CAPSULE,ORAL,2026-11-14,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
5325,EQ 75MG BASE,SUNOSI,AXSOME MALTA,N,211230,2019-06-17,RX,TABLET,ORAL,2026-06-17,INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
5325,EQ 75MG BASE,SUNOSI,AXSOME MALTA,N,211230,2019-06-17,RX,TABLET,ORAL,2024-06-17,NEW CHEMICAL ENTITY
34,EQ 60MG BASE;EQ 5MG BASE;30MG,TRIUMEQ PD,VIIV HLTHCARE,N,215413,2022-03-30,RX,"TABLET, FOR SUSPENSION",ORAL,2026-12-15,PEDIATRIC EXCLUSIVITY
866,EQ 500MG BASE,DICLOXACILLIN SODIUM,AUROBINDO PHARMA,A,216845,2022-09-23,RX,CAPSULE,ORAL,2023-03-29,COMPETITIVE GENERIC THERAPY
353,0.064%;0.005%,WYNZORA,MC2,N,213422,2020-07-20,RX,CREAM,TOPICAL,2023-07-20,NEW DOSAGE FORM
5510,150MG,VIVJOA,MYCOVIA PHARMS,N,215888,2022-04-26,RX,CAPSULE,ORAL,2027-04-26,NEW CHEMICAL ENTITY
5379,100MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2024-06-16,"TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) AND SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN)"
1763,50MG/10ML (5MG/ML),PROVAYBLUE,PROVEPHARM SAS,N,204630,2016-04-08,RX,SOLUTION,INTRAVENOUS,2023-04-08,FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
5285,EQ 20MG BASE,DOPTELET,AKARX INC,N,210238,2018-05-21,RX,TABLET,ORAL,2026-06-26,TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
5729,45MG,VEOZAH,ASTELLAS,N,216578,2023-05-12,RX,TABLET,ORAL,2028-05-12,NEW CHEMICAL ENTITY
4190,EQ 1.5% BASE,OPZELURA,INCYTE CORP,N,215309,2021-09-21,RX,CREAM,TOPICAL,2025-07-18,INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
5302,25MG,LORBRENA,PFIZER,N,210868,2018-11-02,RX,TABLET,ORAL,2025-11-02,INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
3312,5MG/5ML (1MG/ML),CORLANOR,AMGEN INC,N,209964,2019-04-22,RX,SOLUTION,ORAL,2026-04-22,"INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE"
3317,10MG,REVLIMID,CELGENE,N,021880,2005-12-27,RX,CAPSULE,ORAL,2026-05-28,INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
3317,25MG,REVLIMID,CELGENE,N,021880,2006-06-29,RX,CAPSULE,ORAL,2026-05-28,INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
4188,100MG/ML,FERRIPROX,CHIESI,N,208030,2015-09-09,RX,SOLUTION,ORAL,2028-04-30,TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
2806,160MG,DIOVAN,NOVARTIS,N,021283,2001-07-18,RX,TABLET,ORAL,2024-04-19,NEW PATIENT POPULATION
4830,12.5MG;1GM,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,2016-12-09,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
3317,2.5MG,LENALIDOMIDE,DR REDDYS,A,209348,2021-10-14,RX,CAPSULE,ORAL,2023-03-06,PATENT CHALLENGE
5497,EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML),CYTALUX,ON TARGET LABS,N,214907,2021-11-29,RX,SOLUTION,INTRAVENOUS,2028-11-29,AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS IN ADULT PATIENTS WITH OVARIAN CANCER
786,100MG;44MG,VYXEOS,CELATOR PHARMS,N,209401,2017-08-03,RX,POWDER,INTRAVENOUS,2028-03-30,TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER
4190,EQ 25MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2028-09-22,TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
2865,EQ 60MG BASE,GEODON,VIATRIS,N,020825,2001-02-05,RX,CAPSULE,ORAL,2025-01-28,INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
5202,2MG,OLUMIANT,ELI LILLY AND CO,N,207924,2018-05-31,RX,TABLET,ORAL,2023-05-31,NEW CHEMICAL ENTITY
5305,EQ 100MG BASE,VITRAKVI,BAYER HLTHCARE,N,210861,2018-11-26,RX,CAPSULE,ORAL,2025-11-26,INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
4175,5MG;1GM,JENTADUETO XR,BOEHRINGER INGELHEIM,N,208026,2016-05-27,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
5360,5MG,DAYVIGO,EISAI INC,N,212028,2020-04-07,RX,TABLET,ORAL,2026-04-20,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E2006-A001-113
5497,EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML),CYTALUX,ON TARGET LABS,N,214907,2021-11-29,RX,SOLUTION,INTRAVENOUS,2025-12-16,ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT AND NONMALIGNANTPULMONARY LESIONS IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CANCER IN THE LUNG
5472,10MG,QULIPTA,ABBVIE,N,215206,2021-09-28,RX,TABLET,ORAL,2026-09-28,NEW CHEMICAL ENTITY
5511,5MG,CAMZYOS,BRISTOL,N,214998,2022-04-28,RX,CAPSULE,ORAL,2029-04-28,TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
4993,500MG;EQ 20MG BASE,VOQUEZNA DUAL PAK,PHATHOM,N,215153,2022-05-03,DISCN,"CAPSULE, TABLET",ORAL,2027-05-03,NEW CHEMICAL ENTITY
5390,9MG,PEMAZYRE,INCYTE CORP,N,213736,2020-04-17,RX,TABLET,ORAL,2025-04-17,NEW CHEMICAL ENTITY
4110,30MG,JYNARQUE,OTSUKA,N,204441,2018-04-23,RX,TABLET,ORAL,2025-04-23,INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
5356,300MG,OXBRYTA,GLOBAL BLOOD THERAPS,N,216157,2021-12-17,RX,"TABLET, FOR SUSPENSION",ORAL,2028-12-17,FOR TREATMENT OF SICKLE CELL DISEASE (SCD) IN PEDIATRIC PATIENTS 4 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE
5225,10GM/PACKET,LOKELMA,ASTRAZENECA,N,207078,2018-05-18,RX,FOR SUSPENSION,ORAL,2023-04-24,ADDITIONAL INFORMATION ADDED TO THE LABELING REGARDING THE USE IN PATIENTS ON CHRONIC HEMODIALYSIS
5128,500MG IRON/10ML (50MG IRON/ML),INJECTAFER,AM REGENT,N,203565,2020-10-08,RX,SOLUTION,INTRAVENOUS,2024-11-19,NEW PATIENT POPULATION
5274,EQ 50MG BASE;200MG;EQ 25MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2018-02-07,RX,TABLET,ORAL,2024-02-24,LABELING REVISIONS RELATED TO CLINICAL STUDIES
4110,45MG,JYNARQUE,OTSUKA,N,204441,2018-04-23,RX,TABLET,ORAL,2025-04-23,INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
4228,188MG/PACKET;150MG/PACKET,ORKAMBI,VERTEX PHARMS INC,N,211358,2018-08-07,RX,GRANULE,ORAL,2025-08-07,FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
4357,50MG/VIAL,ERAXIS,VICURON HOLDINGS,N,021632,2006-02-17,RX,POWDER,INTRAVENOUS,2023-09-22,NEW PATIENT POPULATION
1118,2MG,AFINITOR DISPERZ,NOVARTIS PHARM,N,203985,2012-08-29,RX,"TABLET, FOR SUSPENSION",ORAL,2025-04-10,FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
5302,100MG,LORBRENA,PFIZER,N,210868,2018-11-02,RX,TABLET,ORAL,2023-11-02,NEW CHEMICAL ENTITY
419,2MG/ACTUATION,BUDESONIDE,PADAGIS ISRAEL,A,215328,2023-04-12,RX,"AEROSOL, FOAM",RECTAL,2023-10-24,COMPETITIVE GENERIC THERAPY
4233,EQ 200MG BASE/2ML (EQ 100MG BASE/ML),BRIDION,MSD SUB MERCK,N,022225,2015-12-15,RX,SOLUTION,INTRAVENOUS,2023-06-09,REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4
4741,EQ 100MG BASE,SIRTURO,JANSSEN THERAP,N,204384,2012-12-28,RX,TABLET,ORAL,2026-08-09,INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
1225,0.055MG/INH;EQ 0.014MG BASE/INH,AIRDUO DIGIHALER,TEVA PHARM,N,208799,2019-07-12,RX,POWDER,INHALATION,2024-07-09,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
4811,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2027-03-19,"TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN"
4566,7.5GM/PACKET,LUMRYZ,AVADEL CNS,N,214755,2023-05-01,RX,"FOR SUSPENSION, EXTENDED RELEASE",ORAL,2026-05-01,NEW PRODUCT
5394,50MG,QINLOCK,DECIPHERA PHARMS,N,213973,2020-05-15,RX,TABLET,ORAL,2025-05-15,NEW CHEMICAL ENTITY
5406,30MG/30ML (1MG/ML),OLINVYK,TREVENA,N,210730,2020-10-30,RX,SOLUTION,INTRAVENOUS,2025-10-30,NEW CHEMICAL ENTITY
2066,4MCG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,ZEMPLAR,ABBVIE,N,021606,2005-05-26,DISCN,CAPSULE,ORAL,2023-10-18,INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4  AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
4190,EQ 1.5% BASE,OPZELURA,INCYTE CORP,N,215309,2021-09-21,RX,CREAM,TOPICAL,2026-01-18,PEDIATRIC EXCLUSIVITY
5267,8MG/3ML (2.68MG/ML),OZEMPIC,NOVO,N,209637,2022-03-28,RX,SOLUTION,SUBCUTANEOUS,2025-03-28,ADDITION OF A 3RD MAINTENANCE DOSE OF SEMAGLUTIDE
4746,3MG,POMALYST,BRISTOL,N,204026,2013-02-08,RX,CAPSULE,ORAL,2027-05-14,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
5468,0.6MG,BYLVAY,ALBIREO,N,215498,2021-07-20,RX,"CAPSULE, PELLETS",ORAL,2026-06-13,TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
5280,EQ 150MG BASE,TAVALISSE,RIGEL PHARMS INC,N,209299,2018-04-17,RX,TABLET,ORAL,2023-04-17,NEW CHEMICAL ENTITY
1533,1%;1.8%;0.4%,PHEXXI,EVOFEM INC,N,208352,2020-05-22,RX,GEL,VAGINAL,2023-05-22,NEW PRODUCT
4191,8MG,TOVIAZ,PFIZER,N,022030,2008-10-31,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-06-17,TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG
5511,5MG,CAMZYOS,BRISTOL,N,214998,2022-04-28,RX,CAPSULE,ORAL,2026-06-15,LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY MYK-461-017
5327,5MG,BALVERSA,JANSSEN BIOTECH,N,212018,2019-04-12,RX,TABLET,ORAL,2024-04-12,NEW CHEMICAL ENTITY
5716,EQ 200MG BASE/VIAL,REZZAYO,CIDARA THERAPS,N,217417,2023-03-22,RX,POWDER,INTRAVENOUS,2028-03-22,NEW CHEMICAL ENTITY
1123,2MG/VIAL,BYDUREON,ASTRAZENECA AB,N,022200,2012-01-27,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2023-08-15,PEDIATRIC EXCLUSIVITY
4228,"100MG, 75MG, 50MG;75MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,217660,2023-04-26,RX,GRANULES,ORAL,2026-04-26,NEW PRODUCT
5388,EQ 10MG BASE,KOSELUGO,ASTRAZENECA,N,213756,2020-04-10,RX,CAPSULE,ORAL,2027-04-10,"INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)"
4318,EQ 30MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2025-04-07,"REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTSFROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST"
5460,20MG;EQ 10MG BASE,LYBALVI,ALKERMES INC,N,213378,2021-05-28,RX,TABLET,ORAL,2026-05-28,NEW CHEMICAL ENTITY
5432,120MG,ORGOVYX,MYOVANT SCIENCES,N,214621,2020-12-18,RX,TABLET,ORAL,2025-12-18,NEW CHEMICAL ENTITY
5356,300MG,OXBRYTA,GLOBAL BLOOD THERAPS,N,216157,2021-12-17,RX,"TABLET, FOR SUSPENSION",ORAL,2024-11-25,NEW CHEMICAL ENTITY
5330,60MG,XPOVIO,KARYOPHARM THERAPS,N,212306,2021-04-15,RX,TABLET,ORAL,2026-07-03,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5231,25MG,RYDAPT,NOVARTIS,N,207997,2017-04-28,RX,CAPSULE,ORAL,2024-04-28,"TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)"
4382,50MG,MYRBETRIQ,APGDI,N,202611,2012-06-28,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-03-25,TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE
328,5%,EPSOLAY,GALDERMA LABS LP,N,214510,2022-04-22,RX,CREAM,TOPICAL,2025-04-22,NEW PRODUCT
2593,100MG;300MG;300MG,DELSTRIGO,MSD MERCK CO,N,210807,2018-08-30,RX,TABLET,ORAL,2025-01-27,NEW PATIENT POPULATION
5379,200MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2020-01-09,RX,TABLET,ORAL,2025-01-09,NEW CHEMICAL ENTITY
2552,EQ 1MG BASE/PACKET,PROGRAF,ASTELLAS,N,210115,2018-05-24,RX,FOR SUSPENSION,ORAL,2025-05-24,"PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS"
4715,EQ 20MG BASE,CABOMETYX,EXELIXIS INC,N,208692,2016-04-25,RX,TABLET,ORAL,2024-09-17,TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
4318,EQ 20MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2025-07-12,PEDIATRIC EXCLUSIVITY
4746,4MG,POMALYST,BRISTOL,N,204026,2013-02-08,RX,CAPSULE,ORAL,2027-05-14,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
4947,372MG,CRESEMBA,ASTELLAS,N,207501,2015-03-06,RX,POWDER,INTRAVENOUS,2020-03-06,NEW CHEMICAL ENTITY
4830,5MG;500MG,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,2015-08-26,RX,TABLET,ORAL,2026-06-20,NEW PATIENT POPULATION
1963,1MG;0.5MG;40MG,MYFEMBREE,MYOVANT SCIENCES,N,214846,2021-05-26,RX,TABLET,ORAL,2025-12-18,NEW CHEMICAL ENTITY
1929,30MG,LAMPIT,BAYER HEALTHCARE,N,213464,2020-08-06,RX,TABLET,ORAL,2027-08-06,INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
5280,EQ 100MG BASE,TAVALISSE,RIGEL PHARMS INC,N,209299,2018-04-17,RX,TABLET,ORAL,2025-04-17,FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
24,3GM/PACKET; 1GM/PACKET,RELYVRIO,AMYLYX,N,216660,2022-09-29,RX,FOR SUSPENSION,ORAL,2027-09-29,NEW CHEMICAL ENTITY
5731,EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL,XACDURO (COPACKAGED),ENTASIS THERAP,N,216974,2023-05-23,RX,POWDER,INTRAVENOUS,2033-05-23,GENERATING ANTIBIOTIC INCENTIVES NOW
5384,EQ 10MG BASE,ISTURISA,RECORDATI RARE,N,212801,2020-03-06,DISCN,TABLET,ORAL,2025-03-06,NEW CHEMICAL ENTITY
1763,10MG/2ML (5MG/ML),PROVAYBLUE,PROVEPHARM SAS,N,204630,2019-07-18,RX,SOLUTION,INTRAVENOUS,2023-04-08,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5154,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2023-03-19,NEW STRENGTH
5270,2.5MG;500MG,SEGLUROMET,MSD SUB MERCK,N,209806,2017-12-19,RX,TABLET,ORAL,2024-09-17,"REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV"
793,36MG,EMFLAZA,PTC THERAP,N,208684,2017-02-09,RX,TABLET,ORAL,2024-02-09,TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
5226,12MG,AUSTEDO,TEVA BRANDED PHARM,N,208082,2017-04-03,RX,TABLET,ORAL,2024-12-24,PEDIATRIC EXCLUSIVITY
2480,250MG/PACKET,DIACOMIT,BIOCODEX SA,N,207223,2018-08-20,RX,FOR SUSPENSION,ORAL,2023-08-20,NEW CHEMICAL ENTITY
2552,EQ 5MG BASE,ASTAGRAF XL,ASTELLAS,N,204096,2013-07-19,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-05-24,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
4810,420MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2024-08-02,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
2066,0.01MG/2ML (0.005MG/ML),ZEMPLAR,ABBVIE,N,020819,2000-02-01,RX,SOLUTION,INTRAVENOUS,2023-10-18,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
1725,2.5MG;500MG,SEGLUROMET,MSD SUB MERCK,N,209806,2017-12-19,RX,TABLET,ORAL,2024-09-17,"REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV"
5346,15MG,RINVOQ,ABBVIE,N,211675,2019-08-16,RX,"TABLET, EXTENDED RELEASE",ORAL,2025-03-16,TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
768,EQ 75MG BASE/PACKET,PROCYSBI,HORIZON,N,213491,2020-02-14,RX,"GRANULE, DELAYED RELEASE",ORAL,2024-12-22,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5352,EQ 1GM BASE/VIAL,FETROJA,SHIONOGI INC,N,209445,2019-11-14,RX,POWDER,INTRAVENOUS,2023-09-25,"INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS"
1725,12.5MG;1GM,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,2015-08-26,RX,TABLET,ORAL,2026-06-20,NEW PATIENT POPULATION
4188,1GM,FERRIPROX,CHIESI,N,021825,2019-07-25,RX,TABLET,ORAL,2028-04-30,"TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011"
5440,400MG/2ML (200MG/ML);600MG/2ML (300MG/ML),CABENUVA KIT,VIIV HLTHCARE,N,212888,2021-01-21,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2025-01-31,NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS
4180,40MG/ML,DIFICID,CUBIST PHARMS LLC,N,213138,2020-01-24,RX,FOR SUSPENSION,ORAL,2023-07-24,PEDIATRIC EXCLUSIVITY
2046,EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML),AKYNZEO,HELSINN HLTHCARE,N,210493,2020-05-27,RX,SOLUTION,INTRAVENOUS,2023-04-19,NEW CHEMICAL ENTITY
4190,EQ 10MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2026-11-24,PEDIATRIC EXCLUSIVITY
195,6.25MG;6.25MG;6.25MG;6.25MG,MYDAYIS,TAKEDA PHARMS USA,N,022063,2017-06-20,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2023-03-13,PEDIATRIC EXCLUSIVITY
5379,50MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2021-06-16,RX,TABLET,ORAL,2027-01-09,"INDICATED FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC GIST HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION, INCLUDING PDGFRA D842V MUTATIONS"
4228,25MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2019-04-29,RX,GRANULE,ORAL,2024-07-31,"TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T"
5092,200MG/2.5ML (80MG/ML),DEFITELIO,JAZZ PHARMS INC,N,208114,2016-03-30,RX,SOLUTION,INTRAVENOUS,2023-03-30,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)."
1845,15MG,MORPHINE SULFATE,HIKMA,N,022207,2008-03-17,RX,TABLET,ORAL,2024-06-02,NEW PATIENT POPULATION
4802,EQ 0.5MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,RX,TABLET,ORAL,2024-12-22,PEDIATRIC EXCLUSIVITY
4550,0.42-8.33mCi/ML,FLUORODOPA F18,FEINSTEIN,N,200655,2019-10-10,RX,SOLUTION,INTRAVENOUS,2024-10-10,NEW CHEMICAL ENTITY
5346,15MG,RINVOQ,ABBVIE,N,211675,2019-08-16,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-08-16,NEW CHEMICAL ENTITY
5506,EQ 50MG BASE,PYRUKYND,AGIOS PHARMS INC,N,216196,2022-02-17,RX,TABLET,ORAL,2027-02-17,NEW CHEMICAL ENTITY
1407,325MG;97.5MG,COMBOGESIC,AFT PHARMS LTD,N,209471,2023-03-01,RX,TABLET,ORAL,2026-03-01,NEW PRODUCT
1539,100MG;300MG;300MG,DELSTRIGO,MSD MERCK CO,N,210807,2018-08-30,RX,TABLET,ORAL,2025-01-27,NEW PATIENT POPULATION
5459,25MG,TRUSELTIQ,HELSINN HLTHCARE,N,214622,2021-05-28,DISCN,CAPSULE,ORAL,2026-05-28,NEW CHEMICAL ENTITY
785,140MG,SPRYCEL,BRISTOL MYERS SQUIBB,N,021986,2010-10-28,RX,TABLET,ORAL,2025-05-09,PEDIATRIC EXCLUSIVITY
5201,2%,EUCRISA,ANACOR PHARMS INC,N,207695,2016-12-14,RX,OINTMENT,TOPICAL,2023-03-23,NEW PATIENT POPULATION
5345,100MG,ROZLYTREK,GENENTECH INC,N,212725,2019-08-15,RX,CAPSULE,ORAL,2026-08-15,"INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTENACE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE EITHER PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY"
4382,25MG,MYRBETRIQ,APGDI,N,202611,2012-06-28,RX,"TABLET, EXTENDED RELEASE",ORAL,2024-03-25,TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE
5143,25MG,ONGENTYS,NEUROCRINE,N,212489,2020-04-24,RX,CAPSULE,ORAL,2025-04-24,NEW CHEMICAL ENTITY
5226,12MG,AUSTEDO,TEVA BRANDED PHARM,N,208082,2017-04-03,RX,TABLET,ORAL,2024-10-03,PEDIATRIC EXCLUSIVITY
2446,0.2%,HYFTOR,NOBELPHARMA,N,213478,2022-03-22,RX,GEL,TOPICAL,2025-03-22,NEW PRODUCT
5399,100% w/w,DOJOLVI,ULTRAGENYX PHARM INC,N,213687,2020-06-30,RX,LIQUID,ORAL,2025-06-30,NEW CHEMICAL ENTITY
4810,70MG/ML,IMBRUVICA,PHARMACYCLICS LLC,N,217003,2022-08-24,RX,SUSPENSION,ORAL,2030-02-24,PEDIATRIC EXCLUSIVITY
4829,20MG,OTEZLA,AMGEN INC,N,205437,2014-03-21,RX,TABLET,ORAL,2023-04-10,INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
3317,20MG,REVLIMID,CELGENE,N,021880,2013-06-05,RX,CAPSULE,ORAL,2026-05-28,INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
3483,300MG/16.7ML (18MG/ML),NOXAFIL,MERCK SHARP DOHME,N,205596,2014-03-13,RX,SOLUTION,INTRAVENOUS,2024-06-17,FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
247,110MG/VIAL,ARTESUNATE,AMIVAS,N,213036,2020-05-26,RX,POWDER,INTRAVENOUS,2025-05-26,NEW CHEMICAL ENTITY
4483,10MG/VIAL,KYPROLIS,ONYX PHARMS AMGEN,N,202714,2018-06-07,RX,POWDER,INTRAVENOUS,2023-08-20,TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE
2389,150MG/0.42ML (150MG/0.42ML),UZEDY,TEVA,N,213586,2023-04-28,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2026-04-28,NEW PRODUCT
1053,EQ 10MG BASE,LEXAPRO,ABBVIE,N,021323,2002-08-14,RX,TABLET,ORAL,2026-05-12,NEW PATIENT POPULATION
5270,7.5MG;1GM,SEGLUROMET,MSD SUB MERCK,N,209806,2017-12-19,RX,TABLET,ORAL,2024-09-17,"REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV"
465,0.064%;0.005%,TACLONEX,LEO PHARMA AS,N,022185,2008-05-09,RX,SUSPENSION,TOPICAL,2023-01-25,PEDIATRIC EXCLUSIVITY
434,24MG/0.48ML (50MG/ML),BRIXADI,BRAEBURN,N,210136,2023-05-23,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2026-05-23,NEW PRODUCT
760,0.1%,VERKAZIA,SANTEN,N,214965,2021-06-23,RX,EMULSION,OPHTHALMIC,2024-06-23,NEW PRODUCT
2676,300MG,THIOLA EC,MISSION PHARMACAL CO,N,211843,2019-06-28,RX,"TABLET, DELAYED RELEASE",ORAL,2026-06-28,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5262,240MG/12ML (20MG/ML),PREVYMIS,MERCK SHARP DOHME,N,209940,2017-11-08,RX,SOLUTION,INTRAVENOUS,2024-11-08,PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
1003,EQ 50MG BASE;200MG;EQ 25MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2018-02-07,RX,TABLET,ORAL,2024-02-24,LABELING REVISIONS RELATED TO CLINICAL STUDIES
4382,8MG/ML,MYRBETRIQ GRANULES,APGDI,N,213801,2021-03-25,RX,"FOR SUSPENSION, EXTENDED RELEASE",ORAL,2024-09-25,PEDIATRIC EXCLUSIVITY
5504,100MG,CIBINQO,PFIZER,N,213871,2022-01-14,RX,TABLET,ORAL,2027-01-14,NEW CHEMICAL ENTITY
5311,75MG,GEMTESA,UROVANT,N,213006,2020-12-23,RX,TABLET,ORAL,2025-12-23,NEW CHEMICAL ENTITY
4310,200MG/20ML (10MG/ML),VIMPAT,UCB INC,N,022254,2008-10-28,RX,SOLUTION,INTRAVENOUS,2023-11-16,ADDITION OF A NEW INDICATION FOR ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
2571,0.1%,TAZAROTENE,COSETTE,A,214136,2022-09-13,RX,GEL,TOPICAL,2023-03-13,COMPETITIVE GENERIC THERAPY
4830,25MG,JARDIANCE,BOEHRINGER INGELHEIM,N,204629,2014-08-01,RX,TABLET,ORAL,2026-12-20,PEDIATRIC EXCLUSIVITY
2457,1MG/ML,VESICARE LS,ASTELLAS,N,209529,2020-05-26,RX,SUSPENSION,ORAL,2023-11-26,PEDIATRIC EXCLUSIVITY
5328,200MG,VIJOICE,NOVARTIS,N,215039,2022-04-05,RX,TABLET,ORAL,2029-04-05,TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH SEVERE MANIFESTATIONS OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) WHO REQUIRE SYSTEMIC THERAPY
5010,94MG/PACKET;75MG/PACKET,ORKAMBI,VERTEX PHARMS INC,N,211358,2022-09-02,RX,GRANULE,ORAL,2025-09-02,NEW STRENGTH
5389,150MG,TUKYSA,SEAGEN,N,213411,2020-04-17,RX,TABLET,ORAL,2026-01-19,"TUCATINIB IN COMBINATION WITH TRASTUZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE, UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY"
5384,EQ 5MG BASE,ISTURISA,RECORDATI RARE,N,212801,2020-03-06,RX,TABLET,ORAL,2025-03-06,NEW CHEMICAL ENTITY
1053,EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,LEXAPRO,ABBVIE,N,021365,2002-11-27,DISCN,SOLUTION,ORAL,2026-05-12,NEW PATIENT POPULATION
5347,EQ 100MG BASE,INREBIC,IMPACT,N,212327,2019-08-16,RX,CAPSULE,ORAL,2026-08-16,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
4944,EQ 30MG BASE;120MG;EQ 15MG BASE,BIKTARVY,GILEAD SCIENCES INC,N,210251,2021-10-07,RX,TABLET,ORAL,2028-10-07,A COMPLETE REGIMEN FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PEDIATRIC PATIENTS WEIGHING 14 KG TO LESS THAN 25 KG WHO HAVE NO ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF BIKTARVY
5232,3.12MG/1.56ML (2MG/ML),TYMLOS,RADIUS HEALTH INC,N,208743,2017-04-28,RX,SOLUTION,SUBCUTANEOUS,2025-12-19,"TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE (DEFINED AS A HISTORY OF OSTEOPOROTIC FRACTURE OR MULTIPLE RISK FACTORS FOR FRACTURE), OR PATIENTS WHO HAVE FAILED OR ARE INTOLERANT TO OTHER AVAILABLE OSTEOPOROSIS THERAPY"
5305,EQ 100MG BASE,VITRAKVI,BAYER HLTHCARE,N,210861,2018-11-26,RX,CAPSULE,ORAL,2023-11-26,NEW CHEMICAL ENTITY
5270,7.5MG;500MG,SEGLUROMET,MSD SUB MERCK,N,209806,2017-12-19,RX,TABLET,ORAL,2024-09-17,"REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV"
4228,50MG/PACKET,KALYDECO,VERTEX PHARMS INC,N,207925,2015-03-17,RX,GRANULE,ORAL,2025-08-15,THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
5372,"50MG,37.5MG,25MG; 75MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2021-06-08,RX,TABLET,ORAL,2028-06-08,FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 6 THROUGH 11 YEARS OLD WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
2391,300MG;100MG,PAXLOVID (COPACKAGED),PFIZER,N,217188,2023-05-25,RX,TABLET,ORAL,2028-05-25,NEW CHEMICAL ENTITY
5341,EQ 17.7MG BASE,VANFLYTA,DAIICHI SANKYO INC,N,216993,2023-07-20,RX,TABLET,ORAL,2030-07-20,"FOR USE IN COMBINATION WITH STANDARD INDUCTION AND CONSOLIDATION, AND AS MAINTENANCE THERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 INTERNAL TANDEM DUPLICATION (ITD)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST"
4810,70MG,IMBRUVICA,PHARMACYCLICS LLC,N,205552,2017-12-20,RX,CAPSULE,ORAL,2030-02-24,PEDIATRIC EXCLUSIVITY
4399,EQ 75MG ACID,PROMACTA,NOVARTIS,N,022291,2009-09-08,RX,TABLET,ORAL,2025-11-16,INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
5508,50MG/ML,ZTALMY,MARINUS,N,215904,2022-06-01,RX,SUSPENSION,ORAL,2027-06-01,NEW CHEMICAL ENTITY
4802,EQ 1MG,MEKINIST,NOVARTIS,N,204114,2013-05-29,DISCN,TABLET,ORAL,2025-06-22,"TRAMETINIB IS INDICATED IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS"
1225,0.055MG/INH;EQ 0.014MG BASE/INH,AIRDUO RESPICLICK,TEVA PHARM,N,208799,2017-01-27,RX,POWDER,INHALATION,2024-07-09,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
4810,140MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2023-05-06,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
2140,EQ 7.5MG BASE;46MG,QSYMIA,VIVUS,N,022580,2012-07-17,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-06-24,NEW PATIENT POPULATION
4566,6GM/PACKET,LUMRYZ,AVADEL CNS,N,214755,2023-05-01,RX,"FOR SUSPENSION, EXTENDED RELEASE",ORAL,2030-05-01,TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULTS WITH NARCOLEPSY
5267,2MG/1.5ML (1.34MG/ML),OZEMPIC,NOVO,N,209637,2017-12-05,RX,SOLUTION,SUBCUTANEOUS,2023-01-16,"REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE"
5330,40MG,XPOVIO,KARYOPHARM THERAPS,N,212306,2021-04-15,RX,TABLET,ORAL,2027-06-22,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5480,0.56MG/VIAL,VOXZOGO,BIOMARIN PHARM,N,214938,2021-11-19,RX,POWDER,SUBCUTANEOUS,2028-11-19,TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
432,133MG/10ML (13.3MG/ML),EXPAREL,PACIRA PHARMS INC,N,022496,2011-10-28,RX,"INJECTABLE, LIPOSOMAL",INJECTION,2024-03-22,NEW PATIENT POPULATION
419,0.16MG/INH;0.0048MG/INH;0.009MG/INH,BREZTRI AEROSPHERE,ASTRAZENECA AB,N,212122,2020-07-23,RX,"AEROSOL, METERED",INHALATION,2023-07-23,NEW COMBINATION
5353,80MG,BRUKINSA,BEIGENE,N,213217,2019-11-14,RX,CAPSULE,ORAL,2026-01-19,TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)  OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
1123,2MG,BYDUREON PEN,ASTRAZENECA AB,N,022200,2014-02-28,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2025-01-22,PEDIATRIC EXCLUSIVITY
5243,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2026-04-30,"TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH"
5110,EQ 123MG BASE,GALAFOLD,AMICUS THERAP US,N,208623,2018-08-10,RX,CAPSULE,ORAL,2023-08-10,NEW CHEMICAL ENTITY
5421,1MG,JESDUVROQ,GLAXOSMITHKLINE,N,216951,2023-02-01,RX,TABLET,ORAL,2028-02-01,NEW CHEMICAL ENTITY
5712,50MG,SKYCLARYS,REATA PHARMS,N,216718,2023-02-28,RX,CAPSULE,ORAL,2030-02-28,TREATMENT OF FRIEDREICHS ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER
5357,100MG/2ML (50MG/ML),VYONDYS 53,SAREPTA THERAPS INC,N,211970,2019-12-12,RX,SOLUTION,INTRAVENOUS,2024-12-12,NEW CHEMICAL ENTITY
5424,EQ 225MG BASE,TEPMETKO,EMD SERONO INC,N,214096,2021-02-03,RX,TABLET,ORAL,2028-02-03,TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING ALTERATIONS
4899,33.75MG;150MG/PACKET,HARVONI,GILEAD SCIENCES INC,N,212477,2019-08-28,RX,PELLETS,ORAL,2026-08-28,"TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN"
3483,300MG/16.7ML (18MG/ML),NOXAFIL,MERCK SHARP DOHME,N,205596,2014-03-13,RX,SOLUTION,INTRAVENOUS,2028-06-17,FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
4318,EQ 20MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2025-10-07,PEDIATRIC EXCLUSIVITY
4947,372MG,CRESEMBA,ASTELLAS,N,207501,2015-03-06,RX,POWDER,INTRAVENOUS,2022-03-06,TREATMENT OF INVASIVE ASPERGILLOSIS
5469,40MG,WELIREG,MERCK SHARP DOHME,N,215383,2021-08-13,RX,TABLET,ORAL,2028-08-13,"TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUORENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY"
5716,EQ 200MG BASE/VIAL,REZZAYO,CIDARA THERAPS,N,217417,2023-03-22,RX,POWDER,INTRAVENOUS,2033-03-22,GENERATING ANTIBIOTIC INCENTIVES NOW
3317,2.5MG,REVLIMID,CELGENE,N,021880,2011-12-21,RX,CAPSULE,ORAL,2024-02-22,"TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)"
4190,EQ 20MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2026-11-24,PEDIATRIC EXCLUSIVITY
5430,EQ 110MG BASE,ORLADEYO,BIOCRYST,N,214094,2020-12-03,RX,CAPSULE,ORAL,2025-12-03,NEW CHEMICAL ENTITY
228,20MG,KYNMOBI,SUMITOMO PHARMA AM,N,210875,2020-05-21,DISCN,FILM,SUBLINGUAL,2023-05-21,NEW PRODUCT
5471,EQ 40MG BASE,EXKIVITY,TAKEDA PHARMS USA,N,215310,2021-09-15,RX,CAPSULE,ORAL,2028-09-15,"TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY"
5267,0.25MG/0.5ML (0.25MG/0.5ML),WEGOVY,NOVO,N,215256,2021-06-04,RX,SOLUTION,SUBCUTANEOUS,2025-12-23,NEW PATIENT POPULATION
5048,EQ 4.45MG BASE,WAKIX,HARMONY,N,211150,2019-08-14,RX,TABLET,ORAL,2024-08-14,NEW CHEMICAL ENTITY
4166,30MG,ELLA,LAB HRA PHARMA,N,022474,2010-08-13,RX,TABLET,ORAL,2024-06-24,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDYHRA2914-5016
5156,2.1-5.5mCi/ML,NETSPOT,AAA USA INC,N,208547,2016-06-01,RX,POWDER,INTRAVENOUS,2023-06-01,"FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS."
4405,1.875GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,WELCHOL,COSETTE,N,022362,2009-10-02,DISCN,FOR SUSPENSION,ORAL,2024-10-20,INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
3909,5%;1.2%,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,ENCUBE,A,212433,2021-04-28,RX,GEL,TOPICAL,2023-03-13,COMPETITIVE GENERIC THERAPY
157,EQ 590MG BASE/8.4ML,ARIKAYCE KIT,INSMED INC,N,207356,2018-09-28,RX,"SUSPENSION, LIPOSOMAL",INHALATION,2025-09-28,TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
5457,1080MG/20ML (54MG/ML),EMPAVELI,APELLIS PHARMS,N,215014,2021-05-14,RX,SOLUTION,SUBCUTANEOUS,2028-05-14,TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
3317,15MG,REVLIMID,CELGENE,N,021880,2006-06-29,RX,CAPSULE,ORAL,2026-05-28,INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
1725,500MG;EQ 50MG BASE,JANUMET XR,MERCK SHARP DOHME,N,202270,2012-02-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-12-04,ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
5202,4MG,OLUMIANT,ELI LILLY AND CO,N,207924,2022-05-10,RX,TABLET,ORAL,2023-05-31,NEW CHEMICAL ENTITY
4190,EQ 25MG BASE,JAKAFI,INCYTE CORP,N,202192,2011-11-16,RX,TABLET,ORAL,2026-11-24,PEDIATRIC EXCLUSIVITY
1118,5MG,AFINITOR,NOVARTIS,N,022334,2009-03-30,RX,TABLET,ORAL,2023-02-26,"TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE"
4634,14MG,TERIFLUNOMIDE,WATSON LABS TEVA,A,209549,2018-07-27,DISCN,TABLET,ORAL,2023-09-08,PATENT CHALLENGE
5259,200MG,VERZENIO,ELI LILLY AND CO,N,208716,2017-09-28,RX,TABLET,ORAL,2024-10-12,NEW PATIENT POPULATION
785,80MG,SPRYCEL,BRISTOL MYERS SQUIBB,N,021986,2010-10-28,RX,TABLET,ORAL,2025-12-21,INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
4182,20MG,XARELTO,JANSSEN PHARMS,N,022406,2011-11-04,RX,TABLET,ORAL,2023-09-10,PEDIATRIC EXCLUSIVITY
4318,EQ 40MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2025-10-07,PEDIATRIC EXCLUSIVITY
5329,EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML),VYLEESI (AUTOINJECTOR),PALATIN TECHNOLOGIES,N,210557,2019-06-21,RX,SOLUTION,SUBCUTANEOUS,2024-06-21,NEW CHEMICAL ENTITY
5339,200MG,INPEFA,LEXICON PHARMS INC,N,216203,2023-05-26,RX,TABLET,ORAL,2028-05-26,NEW CHEMICAL ENTITY
841,6.25MG;6.25MG;6.25MG;6.25MG,MYDAYIS,TAKEDA PHARMS USA,N,022063,2017-06-20,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2023-03-13,PEDIATRIC EXCLUSIVITY
865,25MG,ZIPSOR,ASSERTIO,N,022202,2009-06-16,RX,CAPSULE,ORAL,2024-05-25,NEW PATIENT POPULATION
1349,0.05%,LEXETTE,MAYNE PHARMA,N,210566,2018-05-24,RX,"AEROSOL, FOAM",TOPICAL,2024-08-18,NEW PATIENT POPULATION
4874,10%,JUBLIA,BAUSCH,N,203567,2014-06-06,RX,SOLUTION,TOPICAL,2023-04-27,NEW PATIENT POPULATION
4811,45MG;200MG/PACKET,HARVONI,GILEAD SCIENCES INC,N,212477,2019-08-28,RX,PELLETS,ORAL,2026-08-28,"TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN"
4184,90MG,BRILINTA,ASTRAZENECA,N,022433,2011-07-20,RX,TABLET,ORAL,2025-11-09,PEDIATRIC EXCLUSIVITY
5355,200MG,XCOPRI,SK LIFE,N,212839,2020-03-10,RX,TABLET,ORAL,2025-03-10,NEW CHEMICAL ENTITY
1845,20MG/5ML,MORPHINE SULFATE,HIKMA,N,022195,2008-03-17,RX,SOLUTION,ORAL,2024-06-02,NEW PATIENT POPULATION
785,100MG,SPRYCEL,BRISTOL MYERS SQUIBB,N,021986,2008-05-30,RX,TABLET,ORAL,2025-05-09,PEDIATRIC EXCLUSIVITY
179,10MG/4ML (2.5MG/ML),BARHEMSYS,ACACIA,N,209510,2020-09-01,RX,SOLUTION,INTRAVENOUS,2025-02-26,NEW CHEMICAL ENTITY
852,5MG/SPRAY,VALTOCO,NEURELIS INC,N,211635,2020-01-10,RX,SPRAY,NASAL,2023-01-10,NEW PRODUCT
835,EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML),PRECEDEX,HOSPIRA,N,021038,2013-03-13,RX,INJECTABLE,INJECTION,2025-12-16,NEW PATIENT POPULATION
5291,200MG,TPOXX,SIGA TECHNOLOGIES,N,208627,2018-07-13,RX,CAPSULE,ORAL,2025-07-13,INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
1725,12.5MG;500MG,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,2015-08-26,RX,TABLET,ORAL,2026-06-20,NEW PATIENT POPULATION
3483,300MG/16.7ML (18MG/ML),NOXAFIL,MERCK SHARP DOHME,N,205596,2014-03-13,RX,SOLUTION,INTRAVENOUS,2024-05-31,NEW PATIENT POPULATION
5414,50MG,ZOKINVY,EIGER BIOPHARMS,N,213969,2020-11-20,RX,CAPSULE,ORAL,2025-11-20,NEW CHEMICAL ENTITY
5393,40MG,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,2020-05-08,RX,CAPSULE,ORAL,2027-05-08,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
5244,50MG;20MG/PACKET,MAVYRET,ABBVIE,N,215110,2021-06-10,RX,PELLETS,ORAL,2023-04-10,INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION
4228,"75MG;75MG, 50MG",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,2019-06-21,RX,TABLET,ORAL,2025-02-12,TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
5292,250MG,TIBSOVO,SERVIER,N,211192,2018-07-20,RX,TABLET,ORAL,2025-05-25,"IN COMBINATION WITH AZACITIDINE OR AS MONOTHERAPY FOR THE TREATMENT OFNEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULTS 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY"
4299,150MG,TYBOST,GILEAD SCIENCES INC,N,203094,2014-09-24,RX,TABLET,ORAL,2026-08-22,INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
5226,6MG,AUSTEDO,TEVA BRANDED PHARM,N,208082,2017-04-03,RX,TABLET,ORAL,2024-04-03,TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE
5460,10MG;EQ 10MG BASE,LYBALVI,ALKERMES INC,N,213378,2021-05-28,RX,TABLET,ORAL,2026-05-28,NEW CHEMICAL ENTITY
2552,EQ 1MG BASE,ASTAGRAF XL,ASTELLAS,N,204096,2013-07-19,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2025-05-24,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
4199,0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT,SUFLAVE,BRAINTREE LABS,N,215344,2023-06-15,RX,FOR SOLUTION,ORAL,2026-06-15,NEW PRODUCT
4215,2%;70%,SOLUPREP S,3M HEALTH CARE,N,208288,2018-08-08,OTC,SOLUTION,TOPICAL,2026-01-20,REVISIONS TO THE LABELING TO DESCRIBE MODIFIED FORMULATION BASED ON RESULTS OF STUDIES EM-05-014624 AND EM-05-014815
4830,12.5MG;1GM,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,2015-08-26,RX,TABLET,ORAL,2026-06-20,NEW PATIENT POPULATION
465,0.064%;0.005%,WYNZORA,MC2,N,213422,2020-07-20,RX,CREAM,TOPICAL,2023-07-20,NEW DOSAGE FORM
4175,5MG;1GM,JENTADUETO XR,BOEHRINGER INGELHEIM,N,208026,2016-05-27,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-06-20,"REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST"
1802,5MG/SPRAY,NAYZILAM,UCB INC,N,211321,2019-05-17,RX,SPRAY,NASAL,2026-05-17,"ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER"
353,0.064%;0.005%,ENSTILAR,LEO PHARMA AS,N,207589,2015-10-16,RX,"AEROSOL, FOAM",TOPICAL,2023-01-30,PEDIATRIC EXCLUSIVITY
4188,1GM,FERRIPROX,CHIESI,N,212269,2020-05-19,RX,TABLET,ORAL,2028-04-30,TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
3483,300MG,NOXAFIL POWDERMIX KIT,MSD MERCK CO,N,214770,2021-05-31,RX,"FOR SUSPENSION, DELAYED RELEASE",ORAL,2024-05-31,NEW PRODUCT
4882,20MG,NOURIANZ,KYOWA KIRIN,N,022075,2019-08-27,RX,TABLET,ORAL,2024-08-27,NEW CHEMICAL ENTITY
4801,EQ 75MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2025-04-30,"TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION"
4182,10MG,XARELTO,JANSSEN PHARMS,N,022406,2011-07-01,RX,TABLET,ORAL,2025-02-23,PEDIATRIC EXCLUSIVITY
4801,EQ 75MG BASE,TAFINLAR,NOVARTIS,N,202806,2013-05-29,RX,CAPSULE,ORAL,2024-06-22,"DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER  WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST"
1767,55MG,ADHANSIA XR,PURDUE PHARMA LP,N,212038,2019-02-27,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2024-06-28,LABELING REVISIONS RELATED TO CLINICAL STUDIES
5244,50MG;20MG/PACKET,MAVYRET,ABBVIE,N,215110,2021-06-10,RX,PELLETS,ORAL,2023-03-26,PEDIATRIC EXCLUSIVITY
777,EQ 500MG BASE/VIAL,DALVANCE,ABBVIE,N,021883,2014-05-23,RX,POWDER,INTRAVENOUS,2019-05-23,NEW CHEMICAL ENTITY
5349,EQ 50MG BASE,IBSRELA,ARDELYX INC,N,211801,2019-09-12,RX,TABLET,ORAL,2024-09-12,NEW CHEMICAL ENTITY
4810,70MG,IMBRUVICA,PHARMACYCLICS LLC,N,205552,2017-12-20,RX,CAPSULE,ORAL,2023-05-06,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
2711,56MG;44MG,SEGLENTIS,KOWA PHARMS,N,213426,2021-10-15,RX,TABLET,ORAL,2024-10-15,NEW PRODUCT
605,3%,IHEEZO,HARROW EYE,N,216227,2022-09-27,RX,GEL,OPHTHALMIC,2025-09-27,NEW PRODUCT
5495,EQ 20MG BASE,SCEMBLIX,NOVARTIS,N,215358,2021-10-29,RX,TABLET,ORAL,2028-10-29,"TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP), PREVIOUSLY TREATED WITH TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)"
5343,EQ 200MG BASE,TURALIO,DAIICHI SANKYO INC,N,211810,2019-08-02,DISCN,CAPSULE,ORAL,2026-08-02,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
5133,100MG,VENCLEXTA,ABBVIE,N,208573,2016-04-11,RX,TABLET,ORAL,2025-06-08,"INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
4110,90MG,JYNARQUE,OTSUKA,N,204441,2018-04-23,RX,TABLET,ORAL,2025-04-23,INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
5259,150MG,VERZENIO,ELI LILLY AND CO,N,208716,2017-09-28,RX,TABLET,ORAL,2024-10-12,NEW PATIENT POPULATION
4811,200MG;50MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2020-03-19,RX,TABLET,ORAL,2028-06-10,"FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN"
4810,140MG,IMBRUVICA,PHARMACYCLICS LLC,N,205552,2013-11-13,RX,CAPSULE,ORAL,2025-02-02,PEDIATRIC EXCLUSIVITY
3128,360MG,JADENU SPRINKLE,NOVARTIS,N,207968,2017-05-18,RX,GRANULE,ORAL,2023-07-23,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3
5392,EQ 150MG BASE,TABRECTA,NOVARTIS PHARM,N,213591,2020-05-06,RX,TABLET,ORAL,2027-05-06,INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST
5297,45MG,VIZIMPRO,PFIZER,N,211288,2018-09-27,RX,TABLET,ORAL,2025-09-27,INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
793,18MG,EMFLAZA,PTC THERAP,N,208684,2017-02-09,RX,TABLET,ORAL,2026-06-07,TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
4922,EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL,ZERBAXA,CUBIST PHARMS LLC,N,206829,2014-12-19,RX,POWDER,INTRAVENOUS,2025-04-21,NEW PATIENT POPULATION
5289,75MG,BRAFTOVI,ARRAY BIOPHARMA INC,N,210496,2018-06-27,RX,CAPSULE,ORAL,2025-06-27,"ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST"
4811,400MG;100MG,EPCLUSA,GILEAD SCIENCES INC,N,208341,2016-06-28,RX,TABLET,ORAL,2023-09-19,PEDIATRIC EXCLUSIVITY
5468,1.2MG,BYLVAY,ALBIREO,N,215498,2021-07-20,RX,CAPSULE,ORAL,2030-06-13,TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
4318,EQ 30MG BASE,GILOTRIF,BOEHRINGER INGELHEIM,N,201292,2013-07-12,RX,TABLET,ORAL,2023-04-15,"TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY"
4810,70MG,IMBRUVICA,PHARMACYCLICS LLC,N,205552,2017-12-20,RX,CAPSULE,ORAL,2023-03-04,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
4830,10MG;1GM,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,2016-12-09,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-06-20,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
5382,180MG;10MG,NEXLIZET,ESPERION THERAPS INC,N,211617,2020-02-26,RX,TABLET,ORAL,2023-02-26,NEW PRODUCT
5343,EQ 125MG BASE,TURALIO,DAIICHI SANKYO INC,N,211810,2022-10-14,RX,CAPSULE,ORAL,2026-08-02,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
4944,EQ 25MG BASE,VEMLIDY,GILEAD SCIENCES INC,N,208464,2016-11-10,RX,TABLET,ORAL,2023-08-22,INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4035 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALFAENAMIDE
4866,150MG,ZYKADIA,NOVARTIS,N,205755,2014-04-29,DISCN,CAPSULE,ORAL,2024-05-26,TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
5379,50MG,AYVAKIT,BLUEPRINT MEDICINES,N,212608,2021-06-16,RX,TABLET,ORAL,2024-06-16,"TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) AND SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN)"
785,70MG,SPRYCEL,BRISTOL MYERS SQUIBB,N,021986,2006-06-28,RX,TABLET,ORAL,2026-06-21,PEDIATRIC EXCLUSIVITY
4304,5MG,FARXIGA,ASTRAZENECA AB,N,202293,2014-01-08,RX,TABLET,ORAL,2026-05-08,LABELING REVISIONS RELATED TO STUDY D1699CC00001
5267,0.5MG/0.5ML (0.5MG/0.5ML),WEGOVY,NOVO,N,215256,2021-06-04,RX,SOLUTION,SUBCUTANEOUS,2025-12-23,NEW PATIENT POPULATION
5511,10MG,CAMZYOS,BRISTOL,N,214998,2022-04-28,RX,CAPSULE,ORAL,2029-04-28,TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
5511,2.5MG,CAMZYOS,BRISTOL,N,214998,2022-04-28,RX,CAPSULE,ORAL,2026-06-15,LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY MYK-461-017
4718,5MG/VIAL,GATTEX KIT,TAKEDA PHARMS USA,N,203441,2012-12-21,RX,POWDER,SUBCUTANEOUS,2026-05-16,TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
4830,25MG;1GM,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,2016-12-09,RX,"TABLET, EXTENDED RELEASE",ORAL,2026-06-20,REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
4634,14MG,TERIFLUNOMIDE,AMNEAL PHARMS CO,A,209613,2018-09-28,RX,TABLET,ORAL,2023-09-08,PATENT CHALLENGE
1932,EQ 50MG BASE,TASIGNA,NOVARTIS,N,022068,2018-03-22,RX,CAPSULE,ORAL,2028-09-23,TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH ACCELERATED PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) WITH RESISTANCE ORINTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR (TKI) THERAPY
5303,175MCG/3ML,YUPELRI,MYLAN IRELAND LTD,N,210598,2018-11-09,RX,SOLUTION,INHALATION,2023-11-09,NEW CHEMICAL ENTITY
1239,0.16MG/INH;0.0048MG/INH;0.009MG/INH,BREZTRI AEROSPHERE,ASTRAZENECA AB,N,212122,2020-07-23,RX,"AEROSOL, METERED",INHALATION,2023-07-23,NEW COMBINATION
4811,150MG;37.5MG/PACKET,EPCLUSA,GILEAD SCIENCES INC,N,214187,2021-06-10,RX,PELLETS,ORAL,2028-06-10,"FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN"
5511,10MG,CAMZYOS,BRISTOL,N,214998,2022-04-28,RX,CAPSULE,ORAL,2027-04-28,NEW CHEMICAL ENTITY
112,EQ 70MG BASE/75ML,ALENDRONATE SODIUM,NOVITIUM PHARMA,A,214512,2023-05-11,RX,SOLUTION,ORAL,2023-11-20,COMPETITIVE GENERIC THERAPY
5243,100MG;40MG,MAVYRET,ABBVIE,N,209394,2017-08-03,RX,TABLET,ORAL,2023-04-10,INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION
5393,40MG,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,2020-05-08,RX,CAPSULE,ORAL,2027-05-08,INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
5446,8MG,PONVORY,JANSSEN PHARMS,N,213498,2021-03-18,RX,TABLET,ORAL,2026-03-18,NEW CHEMICAL ENTITY
776,EQ 30MG BASE/PACKET,PRADAXA,BOEHRINGER INGELHEIM,N,214358,2021-06-21,RX,PELLETS,ORAL,2024-06-21,NEW PRODUCT
4810,140MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,RX,TABLET,ORAL,2024-08-02,"FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).  AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)"
5731,EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL,XACDURO (COPACKAGED),ENTASIS THERAP,N,216974,2023-05-23,RX,POWDER,INTRAVENOUS,2028-05-23,NEW CHEMICAL ENTITY
2448,1GM;EQ 50MG BASE,JANUMET XR,MERCK SHARP DOHME,N,202270,2012-02-02,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-02-12,PEDIATRIC EXCLUSIVITY
4946,EQ 0.5GM BASE;2GM/VIAL,AVYCAZ,ALLERGAN,N,206494,2015-02-25,RX,POWDER,INTRAVENOUS,2020-02-25,NEW CHEMICAL ENTITY
776,EQ 50MG BASE/PACKET,PRADAXA,BOEHRINGER INGELHEIM,N,214358,2021-06-21,RX,PELLETS,ORAL,2024-12-21,PEDIATRIC EXCLUSIVITY
4811,150MG;37.5MG/PACKET,EPCLUSA,GILEAD SCIENCES INC,N,214187,2021-06-10,RX,PELLETS,ORAL,2025-04-27,"UPDATES THE US PRESCRIBING INFORMATION WITH CLINICAL DATA REGARDING THE USE OF SOFOSBUVIR AND VELPATASVIR FOR THE TREATMENT OF CHRONIC HCV GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION IN PEOPLE WHO INJECT DRUGS (PWID), INCLUDING THOSE ON MEDICATION-ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER"
2552,EQ 0.5MG BASE,PROGRAF,ASTELLAS,N,050708,1998-08-24,RX,CAPSULE,ORAL,2025-05-24,"PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY OR HEART TRANSPLANTS, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS"
5432,1MG;0.5MG;40MG,MYFEMBREE,MYOVANT SCIENCES,N,214846,2021-05-26,RX,TABLET,ORAL,2025-08-05,FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
888,0.725MG/SPRAY,TRUDHESA,IMPEL PHARMS,N,213436,2021-09-02,RX,"SPRAY, METERED",NASAL,2024-09-02,NEW PRODUCT
5299,EQ 100MG BASE/VIAL,NUZYRA,PARATEK PHARMS INC,N,209817,2018-10-02,RX,POWDER,INTRAVENOUS,2028-10-02,GENERATING ANTIBIOTIC INCENTIVES NOW
5389,50MG,TUKYSA,SEAGEN,N,213411,2020-04-17,RX,TABLET,ORAL,2025-04-17,NEW CHEMICAL ENTITY
1154,EQ 400MG BASE,FENOPROFEN CALCIUM,RISING,A,214475,2022-07-18,RX,CAPSULE,ORAL,2023-02-11,COMPETITIVE GENERIC THERAPY
5390,9MG,PEMAZYRE,INCYTE CORP,N,213736,2020-04-17,RX,TABLET,ORAL,2025-08-26,TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
559,EQ 0.5GM BASE;2GM/VIAL,AVYCAZ,ALLERGAN,N,206494,2015-02-25,RX,POWDER,INTRAVENOUS,2025-02-25,GENERATING ANTIBIOTIC INCENTIVES NOW
4187,200MG,XALKORI,PF PRISM CV,N,202570,2011-08-26,RX,CAPSULE,ORAL,2023-03-11,TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
5440,600MG/3ML (200MG/ML);900MG/3ML (300MG/ML),CABENUVA KIT,VIIV HLTHCARE,N,212888,2021-01-21,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2025-03-29,NEW PATIENT POPULATION
1426,EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL,RECARBRIO,MSD MERCK CO,N,212819,2019-07-16,RX,POWDER,INTRAVENOUS,2024-07-16,NEW CHEMICAL ENTITY
5694,200MG,KRAZATI,MIRATI THERAPS,N,216340,2022-12-12,RX,TABLET,ORAL,2027-12-12,NEW CHEMICAL ENTITY
5155,5MG,OCALIVA,INTERCEPT PHARMS INC,N,207999,2016-05-27,RX,TABLET,ORAL,2023-05-27,"TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA"
4817,EQ 194MG BASE,AEMCOLO,REDHILL,N,210910,2018-11-16,RX,"TABLET, DELAYED RELEASE",ORAL,2023-11-16,NEW CHEMICAL ENTITY
3068,200MG,CARBAGLU,RECORDATI RARE,N,022562,2010-03-18,RX,"TABLET, FOR SUSPENSION",ORAL,2028-01-22,IN PEDIATRIC AND ADULT PATIENTS AS ADJUNCTIVE THERAPY TO STANDARD OF CARE FOR THE TREATMENT OF ACUTE HYPERAMMONEMIA DUE TO PROPIONIC ACIDEMIA (PA) OR METHYLMALONIC ACIDEMIA (MMA)
5305,EQ 25MG BASE,VITRAKVI,BAYER HLTHCARE,N,210861,2018-11-26,RX,CAPSULE,ORAL,2025-11-26,INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT
4518,12.5GM/100ML (125MG/ML),PEDMARK,FENNEC PHARMS INC,N,212937,2022-09-20,RX,SOLUTION,INTRAVENOUS,2025-09-20,NEW PRODUCT
5460,5MG;EQ 10MG BASE,LYBALVI,ALKERMES INC,N,213378,2021-05-28,RX,TABLET,ORAL,2026-05-28,NEW CHEMICAL ENTITY
4947,74.5MG,CRESEMBA,ASTELLAS,N,207500,2022-11-22,RX,CAPSULE,ORAL,2025-03-06,GENERATING ANTIBIOTIC INCENTIVES NOW
4810,560MG,IMBRUVICA,PHARMACYCLICS LLC,N,210563,2018-02-16,DISCN,TABLET,ORAL,2025-08-24,NEW PATIENT POPULATION
5068,75MG,BRIVIACT,UCB INC,N,205836,2016-05-12,RX,TABLET,ORAL,2024-08-27,NEW PATIENT POPULATION
760,0.1%,VEVYE,NOVALIQ GMBH,N,217469,2023-05-30,RX,SOLUTION,OPHTHALMIC,2026-05-30,NEW PRODUCT
5372,"50MG,37.5MG,25MG; 75MG",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,2021-06-08,RX,TABLET,ORAL,2023-02-12,NEW CHEMICAL ENTITY
